Protocol Version:  Amendment 6; 10/24/17   Page 1 of 73 
  
 
 
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable 
SCCHN  
 
Washington University School of Medicine  
Division of Oncology  
660 South Euclid Avenue, Campus Box 8056  
St. Louis, MO  63110  
 
Protocol#: 201404139   
Version Date: 10/24 /17  
 
Coordinating Center:  Washington University School of Medicine  
 
Principal Investigator:  Douglas Adkins , M.D.  
Phone: (314) 362-4471  
E-mail: dadkins@ wustl.edu   
 
Sub-Investigators    Institution     Modality  
Kathryn Trinkaus, Ph.D.   Washington University    Biostatistics  
Tanya Wildes, M.D.    Washington University    Medical Oncology  
Peter Oppelt, M.D.    Washing ton University    Medical Oncology  
Assuntina Sacco, M.D.    University of California – San Diego  Medical Oncology  
Konstantinos Arnaoutakis, M.D.   University of Arkansas    Medical Oncology  
Yifan Tu, M.D., Ph.D.    St. Louis University    Medical Oncology  
Prakash Neupane, M.D.    Kansas University    Medical Oncology  
Nabil Saba, M.D.    Emory University    Medical Oncology  
Conor Steuer, M.D.    Emory University    Medical Oncology  
Frank Worden, M.D.    University of Michigan    Medical Oncology  
Juneko Grilley -Olson , M.D.   University of North Carolina   Medical Oncology  
Ronald Maggiore, M.D.    University of Rochester    Medical Oncology  
Katharine Price, M.D.                          Mayo Clinic                                         Medical Oncology  
 
Study Drug : PD 03 32991 (palbociclib)     
 
IND #:   122402  
Clinical Trials.gov  #:   [STUDY_ID_REMOVED]   
 
CONFIDENTIAL  
The information contained in this document is regarded as confidential and, except to the extent necessary to 
obtain informed consent, may not be disclosed to another party unless law or regulations require such 
disclosure.  Persons to whom the information is disclosed must be informed that the information is 
confidential and may not be further disclosed by them  
  

Protocol Version:  Amendment 6; 10/24/17   Page 2 of 73 
 Phase I/II Trial of the Addition of PD 0332991 t o Cetuximab in Patients with Incurable 
SCCHN  
 
Protocol Revision History  
 
Initial Approval Version        05/06/ 2014 
Amendment #1 Version        07/07/2014  
Amendment #2 Version        12/22/2014  
Amendment #3 Version        12/16 /2015  
Amendment #4 Version        06/07/2016  
Amendment #5 Version        09/06/2017  
Amendment #6 Version        10/24/2017  
  
Protocol Version:  Amendment 6; 10/24/17   Page 3 of 73 
 Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable 
SCCHN  
 
Principal Investigator Signature Page  
 
 
Principal Investigator:   Douglas R. Adkins, M.D.  
 
   
 Signature of Investigator   Date  
 
 
 Printed Name of Investigator    
 By my signature, I agree to personally supervise the 
conduct of this study and to ensure its conduct in 
compliance with the protocol, informed consent, 
IRB/HRPO procedures, the Declaration of Helsinki, ICH 
Good Clinical Practices guidelines, and the applicable 
parts of the United States Code of Federal Regulations or 
local regulations governing the conduct of clinical 
studies.  
 
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 4 of 73 
 Phase I/II Trial of the Addition  of PD 0332991 to Cetuximab in Patients with Incurable 
SCCHN  
 
SCHEMA  
 
 
 
 
 
  
  
      
 
      
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Dose Escalation Schedule (for the Phase I portion ) 
Dose Level  PD 0332991  Dose*  Cetuximab Dose  
Level -1 75 mg  Loading dose : 400 mg/m2 
Weekly thereafter : 250 mg/m2 for 
the duration of study participation  Level 1 (Starting Dose)  100 mg  
Level 2  125 mg  
 
* PD 0332991 is administered on Days 1 through 21 of each  28-day cycle.   Treatment Plan  
PD 0332991 PO Days 1 -21 of each 28 day cycle  
Cetuximab weekly  
Dosing of PD 0332991 for phase II is 125 mg (based 
on Phase I results)  
 
CT scans every 2 cycles  Eligible Patients  
 Incurable SCCHN  
 Any (or no) prior therapy acceptable for phase I; prior treatment with a 
platin agent for Arm 1 of phase II; prior treatment with cetuximab for Arms 
2 and 3 of phase II  
 Prior treatment with cetuximab acceptable for phase I and for Arms 2 and 3 
of phase II only  
 HPV -related or -unrelated for phase I; only HPV -unrelated for Arms 1 and 
2 of phase II ; only HPV -related for Arm 3 of phase II  
Protocol Version:  Amendment 6; 10/24/17   Page 5 of 73 
 Glossary of Abbreviations  
 
AE Adverse event  
ALT (SGPT)  Alanine transaminase (serum glutamate pyruvic transaminase)  
ANC  Absolute neutrophil count  
AST (SGOT)  Aspartate transaminase (serum glutamic oxaloacetic transaminase)  
AUC  Area under the curve  
B-HCG  Beta human chorionic gonadotropin  
CBC  Complete blood count  
CDK  Cyclin dependent kinase  
CR Complete response  
CRF  Case report form  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP  Cancer Therapy Evaluation Program  
DLTs  Dose Limiting Toxicities  
DNA  deoxyribonucleic acid  
DSM  Data and Safety Monitoring  
ECG (or EKG)  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EGFR  Epidermal growth factor receptor  
ER Estrogen receptor  
FDA  Food and Drug Administration  
FFPE  Formalin -fixed paraffin -embedded  
FISH  fluorescent in situ hybridization  
FWA  Federal wide assurance  
GI Gastrointestinal  
HIV Human Immunodeficiency Virus  
HPV  Human papilloma virus  
HRPO  Human Research Protection Office (IRB)  
HSR  Hypersensitivity reaction  
IHC Immunohistochemistry  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
IULN  Institutional upper limit of normal  
IV Intravenous (i.v.)  
IVPB  IV push bolus  
LFT Liver  function test  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose  
NCI National Cancer Institute  
Protocol Version:  Amendment 6; 10/24/17   Page 6 of 73 
 NIH National Institutes of Health  
OHRP  Office of Human Research Protections  
OPSCC  Oropharyngeal squamous cell carcinoma  
OS Overall survival  
PD Progressive disease  
PDX  Patient derived xenograft  
PET Positron emission tomography  
PFS Progression -free survival  
PI Principal investigator  
PK Pharmacokinetic  
PR Partial response  
PT Prothrombin time  
PTT Partial thromboplastin time  
QASMC  Quality Assurance and Safety Monitoring Committee  
QD Quaque die (once a day)  
QTc Corrected QT interval  
RECIST  Response Evaluation Criteria in Solid Tumors (Committee)  
SAE  Serious adverse event  
SCC  Siteman Cancer Center  
SCCHN  Squamous cell carcinoma of the head and neck  
SD Stable disease  
TTP Time to progression  
UPN  Unique patient number  
US Ultrasound  
WHO  World Health Organization  
  
Protocol Version:  Amendment 6; 10/24/17   Page 7 of 73 
 Table of Contents  
SCHEMA  ................................ ................................ ................................ ................................ ........  4 
1.0 BACKGROUND AND RATIONALE  ................................ ................................ ................  9 
1.1 Squamous Cell Carcinoma of the Head and Neck  ................................ ...........................  9 
1.2 EGFR  ................................ ................................ ................................ ................................  9 
1.3 CCND1 and p16 in SCCHN ................................ ................................ .............................  9 
1.4 CDK4/6  ................................ ................................ ................................ ..........................  10 
1.5 Investigationa l Agent(s)  ................................ ................................ ................................ . 10 
1.6 CDK4/6 Inhibition in HNSCC: Pre -Clinical Evidence of Tumor Response  .................  12 
1.7 Study Rationale  ................................ ................................ ................................ ..............  13 
1.8 Amendment 6: Addition of Arm 3 to Phase II  ................................ ...............................  14 
1.9 Correlative Studies Background ................................ ................................ .....................  15 
2.0 OBJECTIVES  ................................ ................................ ................................ ....................  15 
2.1 Primary Objectives  ................................ ................................ ................................ .........  15 
2.2 Secondary Objectives  ................................ ................................ ................................ ..... 16 
2.3 Exploratory Objectives  ................................ ................................ ................................ ... 16 
3.0 PATIENT SELECTION  ................................ ................................ ................................ .... 16 
3.1 Inclusion Criteria  ................................ ................................ ................................ ............  16 
3.2 Exclusion Criteria  ................................ ................................ ................................ ...........  18 
3.3 Inclusion of Women and Minorities ................................ ................................ ...............  19 
4.0 REGISTRATION PROCEDURES  ................................ ................................ ...................  19 
4.1 Confirmation of Patient Eligibility  ................................ ................................ .................  19 
4.2 Patient Registration in the Siteman Cancer Center OnCore Database  ...........................  20 
4.3 Assignment of UPN  ................................ ................................ ................................ ....... 20 
5.0 TREATMENT PLAN  ................................ ................................ ................................ ........  20 
5.1 Premed ication for Cetuximab ................................ ................................ .........................  20 
5.2 Agent Administration  ................................ ................................ ................................ ..... 20 
5.3 Re-Treatment Criteria  ................................ ................................ ................................ .... 21 
5.4 Dose Escalation Schema for Phase I  ................................ ................................ ..............  22 
5.5 Definition of MTD, DLT, Dose Escalation Criteria, and Toxicity, Response, and DLT 
Evaluations for Phase I  ................................ ................................ ................................ ..............  22 
5.6 Dosing for Phase II  ................................ ................................ ................................ .........  23 
5.7 General Concomitant Medication and Supportive Care Guidelines  ..............................  24 
5.8 Women of Childbearing Potential  ................................ ................................ ..................  24 
5.9 Duration of Therapy  ................................ ................................ ................................ ....... 24 
5.10 Duration of Follow -up ................................ ................................ ................................ .... 25 
6.0 DOSE DELAYS/DOSE MODIFICATIONS  ................................ ................................ .... 25 
6.1 Dose Modifications for PD 0332991  ................................ ................................ .............  25 
6.2 Dose Modifications or Delays for Cetuximab ................................ ................................  26 
7.0 REGULATORY AND REPORTING REQUIREMENTS  ................................ ...............  29 
7.1 Definitions  ................................ ................................ ................................ ......................  29 
7.2 Reporting to the Human Research Protection Office (HRPO) at Washington University
 31 
7.3 Reporting to the Quality Assurance and Safety Monitoring Committee (QASMC) at 
Washington University  ................................ ................................ ................................ ..............  32 
7.4 Reporting Requirements for Secondary Sites  ................................ ................................  32 
Protocol Version:  Amendment 6; 10/24/17   Page 8 of 73 
 7.5 Reporting to Secondary Sites  ................................ ................................ .........................  32 
7.6 Reporting to the FDA  ................................ ................................ ................................ ..... 33 
7.7 Reporting to Pfizer  ................................ ................................ ................................ .........  33 
7.8 Timeframe for Reporting Required Events  ................................ ................................ .... 34 
8.0 PHARMACEUTICAL INFORMATION  ................................ ................................ ..........  34 
8.1 PD 0332991 (Palbociclib)  ................................ ................................ ..............................  34 
8.2 Cetuximab (Erbitux)  ................................ ................................ ................................ ....... 41 
9.0 CORRELATIVE STUDIES  ................................ ................................ ..............................  44 
9.1 Optional Tumor Biopsy  ................................ ................................ ................................ .. 44 
9.2 Archival Tumor Tissue ................................ ................................ ................................ ... 45 
9.3 Blood for Pharmacokinetic Analysis ................................ ................................ ..............  45 
9.4 Quality of Life  ................................ ................................ ................................ ................  46 
10.0 STUDY CALENDAR  ................................ ................................ ................................ ....... 47 
11.0 DAT A SUBMISSION SCHEDULE  ................................ ................................ .................  47 
12.0 MEASUREMENT OF EFFECT ................................ ................................ ........................  48 
12.1 Antitumor Effect – Solid Tumors ................................ ................................ ...................  48 
12.2 Disease Parameters  ................................ ................................ ................................ .........  49 
12.3 Methods for Evaluation of Measurable Disease  ................................ ............................  50 
12.4 Response Criteria  ................................ ................................ ................................ ...........  52 
13.0 DATA AND SAFETY MONITORING  ................................ ................................ ............  55 
14.0 AUDITING  ................................ ................................ ................................ ........................  56 
15.0 STATISTICAL CONSIDERATIONS ................................ ................................ ...............  57 
15.1 Correlative Studies  ................................ ................................ ................................ .........  59 
16.0 MULTICENTER REGULATORY REQUIREMENTS  ................................ ...................  59 
17.0 REFERENCES  ................................ ................................ ................................ ..................  61 
APPENDIX A: ECOG Performance Status Scale  ................................ ................................ ........  64 
APPENDIX B: Medication Diary  ................................ ................................ ................................ . 65 
APPENDIX C: Pfizer Reportable Event Cover Sheet  ................................ ................................ .. 66 
APPENDIX D: CYP3A4 Inhibitors, Inducers, and Substrates ................................ .....................  67 
APPENDIX E: EORTC QLQ -C30 ................................ ................................ ...............................  69 
APPENDIX F: FACT -H&N  ................................ ................................ ................................ .........  71 
  
Protocol Version:  Amendment 6; 10/24/17   Page 9 of 73 
  
1.0 BACKGROUND AND RATION ALE 
 
1.1 Squamous Cell Carcinoma of the Head and Neck  
 
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer.  
Approximately 600,000 new cases occur yearly, and most patients present with locally 
advanced disease.  Current multimodality therap y results in 5 -year overall survival (OS) of 
only 40 -50%.  
 
SCCHN is a heterogeneous disease which is not completely defined by clinical variables 
such as primary tumor stage, nodal stage, and sub -site. Smoking is the most common 
etiologic agent.  More recently, human papillomavirus (HPV) was shown to be an 
importa nt causative agent in oropharyngeal SCC (OPSCC).  Assessment of p16 by 
immunohistochemistry (IHC) is an excellent surrogate marker of transcriptionally active 
HPV in OPSCC since nearly all cases of HPV -related OPSCC will demonstrate strong and 
diffuse stai ning for p16.  OPSCC due to HPV carries a much better prognosis compared to 
OPSCC due to smoking, establishing the importance of HPV as a s tratification variable in 
OPSCC.1 
 
Gene expression profiling has highlighted the heterogeneity of SCCHN.  Chung, et al 
identified four subtypes of SCCHN using expression profiling: 1) EGFR enriched, 2) 
mesenchymal -like, 3) normal tonsil -like, and 4) anti -oxidant enriched.2-3 Prognosis varied 
amongst these subgroups.  Importantly, the unique gene expression profile of ea ch 
subgroup shed light on potential molecular drivers which can define tumors likely to be 
sensitive or resistant to selected targeted therapies.  
 
1.2 EGFR  
 
EGFR is overexpressed in many cases of SCCHN and is clearly important in this disease.  
Cetuximab, a mo noclonal antibody against EGFR, is the only molecularly targeted therapy 
to date that has been shown to improve OS in SCCHN.4-5 These data are proof -of-principle 
that defining the molecular drivers of the various subsets of SCCHN can lead to further 
improv ements in treatment outcomes.  However, the relative benefit of cetuximab in the 
treatment of SCCHN has been modest, suggesting that most cases of SCCHN are primarily 
dependent on non -EGFR molecular drivers.  
 
1.3 CCND1 and p16 in SCCHN  
 
CCND1, which encodes cy clin D1, is amplified in 80% or more cases of HPV -unrelated 
SCCHN6 and is a marker of poor prognosis.7-15  Internal data from this institution (J.  Lewis, 
unpublished observations) showed that 116 of 121 (96%) cases of HPV -unrelated SCCHN 
had expression of cyclin D1 as assessed by IHC, and in the majority of cases, ≥ 20% of 
nuclei stained positive (range, 1 -95%).  These observations did not vary across subsites as 
nearly all cases of larynx, hypopharynx, oral cavity and HPV -unrelated oropharynx 
SCCHN had exp ression of cyclin D1 by IHC.  In contrast, CCND1 is overexpressed in 
Protocol Version:  Amendment 6; 10/24/17   Page 10 of 73 
 only 14% of cases of HPV -related OPSCC.16 CDKN2A , which encodes p16INK4a, is 
inactivated in most cases of HPV -unrelated SCCHN by mutation, methylation in 
combination with chromosome loss or by homozygous deletion.17 Over expression of 
cyclin D1 along with decreased expression of p16 and abrogation of p53 function cause 
cellular immortalization of oral keratinocytes.18 Thus, cyclin D1 over expression in the 
context of decreased expression o f p16 is likely to be an important driver of HPV -
unrelated SCCHN.    
 
The consequences of cyclin D1 amplification for response to therapy are not well 
characterized; however, emerging data suggests that cyclin D1 amplification may 
adversely affect response of SCCHN tumors to the two most effective drugs used in the 
treatment of this disease: EGFR inhibitors and cisplatin.  CCND1 is one of the many genes 
induced by intranuclear EGFR, linking cell cycle progression to EGFR stimulation.19  Data 
from SCCHN cell lines suggest an association between resistance to EGFR inhibitors and 
cyclin D1 amplification and/or overexpression.20  In EGFR -mutant lung cancer cells, cyclin 
D1 expression was higher in comparison to EGFR -wild type cells.21  EGFR -mutant 
gefitinib -resistant lung cancer cells were sensitive to the CDK inhibitor flavopiridol, 
confirming the importance of the cycle D axis as a key downstream effector of mutant 
EGFR signaling.  Cyclin D1 overexpression in SCCHN was associated with cisplatin 
resistance in vit ro and in vivo 22, 23 and data from patients with SCCHN has emerged that 
supports a similar relationship of cyclin D1 expression as a predictive biomarker of 
cisplatin resistance.24   
 
1.4 CDK4/6  
 
Cycl in-dependent kinases (CDKs), play a key role in regulating cell cycle progression and 
manage cellular transitions from growth phase (G1 and G2) into phases associated with 
DNA repl ication (S) and mitosis (M).25,26 Interaction between CDKs and cyclin proteins, 
such as cyclin D, has been shown to be crucial in the p rogression  of G1 to S in the cell 
cycle.27  Deregulation of aspects of the cell -cycle, including CDKs, have been shown to 
contribute to the development of cancer.25,27 CDK4 and CDK6 are two closely related 
kinases that enable tumor cell progression during phase G 1 to phase S in the cell cycle.26  
CDK 4 and 6 stimulate cell cycle progression, necessary for DNA replication and for cell 
division,  in combination with cyclin D.26  In preclinical studies, increased levels of cyclin 
D and decreased levels of p16, a naturally occurring inhibitor of CDK4, have been 
associated with increased sensitivity to CDK 4 and 6 inhibition.27  Preclinical studies 
suggest that inhibition of cyclin D -dependent kinase act ivity may prevent tumor growth.26  
Inhibition of CDK 4 and 6 has been shown to prevent the deactivation of retinoblastoma 
(Rb), a tumor suppressor protein, and interfe re with tumor cell progression.28 
  
1.5 Investigational Agent(s)  
 
PD 0332991 is an investigational, orally active and highly selective inhibitor  of the CDK4 
and CDK6 kinases26 with low activity against a panel of 36 other protein kinases.  PD 
0332991 showed antiproliferative effects on Rb -positive cells in vitro and inhibition of 
tumor growth in several Rb -positive human breast and colon xenografts.26 In these models, 
Protocol Version:  Amendment 6; 10/24/17   Page 11 of 73 
 PD 033299 1 resulted in decreased Rb phosphorylation and decreased Ki -67 expression.26 
PD 0332991 showed no activity in Rb -negative tumor xenografts.26  
 
Pfizer is evaluating PD 0332991 in multiple phase I, phase II, and phase III  studies .  Two 
phase I trials evalua ted single agent administration of PD 0332991 to patients with Rb -
positive cancers.29,30 One of these trials determined that the dose -limiting toxicity (DLT) 
of PD 0332991 was neutropenia and the maximum tolerated dose (MTD) was 125 mg once 
daily when admi nistered for 21 of 28 days (3/1 schedule).29 The most common non -
hematologic adverse events included fatigue, nausea, and diarrhea.  The mean half -life of 
PD 0332991 was 25.9 hours.  Patients were selected for Rb -positive cancers, based on IHC 
stain, defin ed as positive if staining intensity was 1+ or greater above background.  Stable 
disease for ≥ 4 cycles (16 weeks) occurred in 27% of evaluable patients and in a number 
of tumor types (liposarcoma, testicular, renal, ovarian, breast, appendiceal, peritonea l, 
melanoma, thymoma and lung).  Another phase I trial of PD 0332991 using an alternative 
dosing plan (21 day cycles; 2/1 schedule) observed a similar likelihood of disease control 
in a variety of tumor types.30 These studies demonstrate that PD 0332991 ha s substantial 
activity in Rb -positive tumors.  
  
Results of a  phase I study in estrogen -receptor positive, HER2 -negative advanced breast 
cancer not selected for cyclin D1 amplification and/or p16 loss showed that the 
combination of PD 0332991 and letrozole  was generally well tolerated, with the 
recommended dose of PD 0 332991 to be 125 mg once daily.31  A second  study was a 
randomized phase II trial initiated to determine the overall safety and efficacy of PD 
0332991 (125 mg) and letrozole (2.5 mg) versus le trozole alone in post -menopausal 
women with ER+ HER2 - advanced breast cancer.32,33  Patients’ tumors were either 
unselected (Part 1) or selected (Part 2) for presence of biomarkers: cyclin D1 amplification 
by FISH and/or p16 loss.  In Part 1 of the trial, the objective response rate was 27% versus 
23% with PD 0332991 plus letrozole versus letrozole alone and the clinical benefit rate 
was 59% versus 44%, respectively.32 When Parts 1 and 2 of the trial were combined, the 
objective response rate was 45% for th ose women who received PD 0332991 plus letrozole 
versus 31% for those who received letrozole alone.  The clinical benefit rate (defined as 
complete response plus partial response plus stable disease for ≥24 weeks) was 70% versus 
44%, respectively.  The dif ferences observed in the objective response rate and clinical 
benefit rate were statistically significant.  Importantly, the median progression -free 
survival (PFS) was significantly different (26.2 versus 7.5 months) favoring the 
combination arm.  The most  frequently reported treatment -related Grade 3/4 adverse events 
(AEs) in patients who received the combination therapy were neutropenia, leukopenia, 
anemia and fatigue.  
  
PD 0332991 is also active in relapsed mantle cell lymphoma selected for cyclin D1 
overexpression.34 The objective response (CR or PR) rate was 18% and the stable disease 
rate was 41%.  Significant reductions in phospho -Rb (89%) and Ki -67 (74%) occurred in 
paired biopsy samples after treatment with PD 0332991.  
   
Taken together, these data provide sound evidence that inhibition of CDK4 and CDK6 
kinases can be effective treatment for cancer that is selected for cyclin D1 amplification 
Protocol Version:  Amendment 6; 10/24/17   Page 12 of 73 
 and/or p16 loss.  
 
1.6 CDK4/6 Inhibition in HNSCC: Pre -Clinical Evidence of Tumor Response  
 
Dr. Loren Michel in o ur group generated cisplatin -resistant derivative SCC1 cell lines from 
cisplatin -sensitive SCC1 by continuous exposure to cisplatin. The IC50 of cisplatin -
resistant derivative SCC1 was three -fold higher than that of cisplatin -sensitive SCC1 (31.3 
uM and 11 .8 uM, respectively).  
Generation of Cisplatin Resistant Derivative Cell Lines from Human Head and Neck 
Squamous Cell Cancer Lines
 
Cisplatin -resistant and cisplatin -sensitive SCC1 cell lines were then exposed to varying 
concentrations of PD 0332991, and the IC50 of the two cell lines to PD 0332991 were 
compared. As seen, the IC50 of cisplatin -resistant derivative SCC1 was 2.5 fold lower than 
that of cisplatin -sensitive SCC1 (293.1 nM and 722.2 nM, respectively) showing that 
cisplatin -resistant SCC1 is hypersensitive to PD 0332991 compared to cisplatin -sensitive 
SCC1.  
Cisplatin -Resistant Cells are Hypersensitive to PD0332991 
 
These data were replicated in another cell line (SCC25), in which the IC50 of cisplatin -
Protocol Version:  Amendment 6; 10/24/17   Page 13 of 73 
 resistant derivative SCC25 was 4.0 fold lower than that of cisplatin -sensitive SCC25.  
 
The effects of CDK 4/6 inhibition on cetuximab activity was the n investigated in the SCC1 
cell line. The data shown supports that: 1) co -exposure of PD 0332991 and cetuximab adds 
to the anti -proliferative effects of cetuximab alone, and 2) PD 0332991 alone has anti -
proliferative effects on the SCC1 cell line.   
How Does Cyclin D Inhibition Influence Cetuximab Activity? 
Control
PD0332991Cell Number
Dr. Van Tine’s laboratory is interested in: 1) validating the efficacy of PD 0332991 in 
patient -derived xenograft (PDX) models in the clinical context of cisplatin resistance and 
cetuximab synergy, and 2) identifying the mechanisms  and hence the biomarkers that 
predict hypersensitivity to CDK 4/6 inhibition using the cisplatin -resistant cell lines his 
laboratory has generated as tools for this undertaking.  
 
1.7 Study Rationale  
 
Most patients with locally advanced HPV -unrelated SCCHN develop recurrent cancer and 
all patients with metastatic SCCHN ultimately die due to the disease.  The EGFR inhibitor 
cetuximab is an important recent addition to the standard treatment options for S CCHN but 
has resulted in only modest improvements in clinical outcomes.  New treatments are 
needed.   
 
Over expression of cyclin D1 and inactivation of p16 occur in the vast majority of cases of 
HPV -unrelated SCCHN.  Genomic characterization of oral SCCHN identified 
amplification of CCND1 and/or loss of CDKN2A (p16) were found in 94% of tumors, 
supporting that cell cycle alterations were a nearly universal feature.35 Resistance to EGFR 
inhibitors and to cisplatin, the two most effective systemic agents in S CCHN, may be in 
part mediated by cyclin D1 overexpression which can be targeted with inhibitors of the 
cyclin D axis.  PD 0332991 is a selective inhibitor of CDK4 and CDK6 kinases, which 
enhanced tumor response to letrozole in women with metastatic breast cancer selected for 
Protocol Version:  Amendment 6; 10/24/17   Page 14 of 73 
 the presence of cyclin D1 amplification and/or p16 loss.  PD 0332991 also has efficacy in 
cyclin D1 overexpressing mantle cell lymphoma and has activity in a broad range of other 
solid tumors.  
 
Our laboratory investigation of PD 033299 1 in the SSC1 cell line demonstrated:  1) the 
IC50 of  cisplatin -resistant derivative SCC1 to PD 0332991 was 2.5 fold lower than that of 
cisplatin -sensitive SCC1 (293.1 nM and 722.2 nM, respectively) showing that cisplatin -
resistant SCC1 is hypersensitive t o PD 0332991 compared to cisplatin -sensitive SCC1, 2) 
co-exposure of PD 0332991 and cetuximab adds to the anti -proliferative effects of 
cetuximab alone, and 3) PD 0332991 alone has anti -proliferative effects on the SCC1 cell 
line. These preclinical data su pport the conclusions that PD 0332991 has single agent 
activity in HNSCC, PD 0332991 is more effective against cisplatin -resistant than cisplatin -
sensitive HNSCC, and PD 0332991 and cetuximab are synergistic against HNSCC.     
 
Based on the evidence presen ted, we propose a phase I/II trial to test our hypotheses that 
the addition of PD 0332991 to cetuximab will be feasible and will improve tumor response 
rate and time -to-progression (TTP) in patients with platin -resistant  incurable SCCHN in 
comparison to hi storical controls.  In the phase II portion of the trial, patients will be 
required to have HPV -unrelated SCCHN tumors (which as a group are known to have 
nearly universal cyclin D1 overexpression or amplification and/or p16 loss) to enrich the 
likelihood of clinical benefit of PD 0332991. Cetuximab will be used as the platform to 
add PD 0332991 to since cetuximab is the current standard FDA -approved treatment 
indicated for patients with platin -resistant  incurable SCCHN.  
 
1.8 Amendment 6: Addition of Arm 3  to Phase II  
 
The genomics of HPV -related SCCHN has been characterized predominantly in primary 
(untreated) tumor specimens. In primary HPV -related SCCHN, overexpression of p16 is 
a physiologic response to binding of the E7 viral oncoprotein to Rb. The normal function 
of p16 to inhibit the complex of CDK 4/6 and cyclin D is inconsequential due to the 
downstream alteration of R b function by E7. Since palbociclib inhibits at a step upstream 
of pRb, palbociclib would not be expected to benefit patients with untrea ted HPV -related 
SCCHN.  
 
However, recent work found that the genomics of recurrent/metastatic (RM) HPV -related 
SCCHN more closely resembles that of HPV -unrelated SCCHN .36 In particular, the 
frequencies of TP53 mutations (15%), whole genome duplication (25% ), and 3p deletion 
(55%) were significantly higher in RM tumors compared to primary tumors. Mutations in 
CDKN2A and amplification of 11q13 were observed in RM HPV -related SCCHN.  
 
These data suggest that RM HPV -related SCCHN may respond to a CDK 4/6 inhibi tor 
like palbociclib. Based on these observations, and the potential of palbociclib to inhibit 
one mechanism of resistance to EGFR inhibitors, we hypothesize palbociclib and 
cetuximab will result in tumor responses in patients with cetuximab -resistant RM H PV-
related SCCHN. Arm 3 will enroll only patients with cetuximab -resistant disease, for 
which there are few , if any , standard treatment options.  
Protocol Version:  Amendment 6; 10/24/17   Page 15 of 73 
  
1.9 Correlative Studies Background  
 
The purpose of the correlative studies is to correlate overall response and TT P to cyclin D1 
expression and p16 loss, both assessed by IHC, in Phase II patients with HPV -unrelated 
SCCHN treated with PD 0332991 and cetuximab.  The methodology for assessment of 
cyclin D1 and p16 by IHC has been previously described.16 At this time, a review of the 
literature does not clearly define the optimal methodology or cut thresholds for a positive 
and a negative result for cyclin D1 expression as it relates to clinical effect of PD 0332991 
or other cell cycle inhibitors.  IHC was chosen as the m ethod to assess cyclin D1 expression 
in this study since it is a widely available methodology for assessing protein expression 
that is familiar to most investigators and clinical laboratories.  For similar reasons, p16 will 
also be assessed by IHC although  a generally agreed upon definition for positive p16 
(>50%; 3+ or 4+) and negative p16 (Negative or <50%; 1+ or 2+) results are available.16 
However, these definitions are geared toward HPV -related OPSCC which are nearly 
always strongly and diffusely posit ive for p16 by IHC.  In our experience, HPV -unrelated 
OPSCC and SCCHN from other subsites are nearly always p16 negative (that is, truly no 
staining).  Thus, for the purposes of the correlative studies in this trial, we will define 
negative p16 to mean no staining and positive p16 to mean any staining.  
     
Patients who participate on the Phase II portion of the trial (Arms 1 and 2 only) will be 
asked to consent to optional pre-Cycle 1  and post-Cycle 2 (to be collected anytime between 
Days 15 and 21 inclusive  and at disease progression ) tumor biopsies (core or 
excisional/incisional) to perform p16 expression, Ki-67 by IHC, total and phospho -Rb by 
IHC, Cyclin D1 by IHC, and TUNEL assay , and to analyze other potential biomarkers as 
they emerge from the scientific understanding of PD0332991 activity  on formalin -fixed 
paraffin -embedded (FFPE) tissue.  The major function of cyclin D -CDK4/6 complexes is 
to promote S phase entry.  This can best be assayed by examining the effects of PD 0332991 
on the proliferation marker Ki -67.  Suppression of the activity of cyclin -CDK4/6 activity 
is predicted to decrease proliferation, the readout of which will be reduced percentage of 
cells staining positive for Ki-67 post -treatment.  In addition, PD 0332991 should only be 
active in tumors that are Rb positive.  Moreover, Rb is a substrate of cyclin D -CDK4/6. 
Therefore, measurement of total and phospho -Rb, which have served as pharmacodynamic 
markers for PD 033299 1 in other clinical trials, will be evaluated.  This agent should not 
affect total Rb, but suppress phospho -Rb.  Lastly, to determine whether changes in 
proliferation and Rb phosphorylation are associated with an increase in apoptosis, TUNEL 
assay will be performed.  All of these assays can be completed on FFPE tissue.   
 
 
2.0 OBJECTIVES  
 
2.1 Primary Objectives  
 
1. Phase I: To determine the maximum tolerated dose of PD 0332991 when administered 
in combination with cetuximab to patients with incurable SCCHN  
Protocol Version:  Amendment 6; 10/24/17   Page 16 of 73 
 2. Phase II , Arm 1 : To determine the efficacy of PD 0332991 in combination with 
cetuximab in incurable platin -resistant  HPV -unrelated SCCHN . Efficacy will be 
measured by the overall response rate  (ORR= CR+PR) defined by RECIST criteria . 
3. Phase II, Arm 2: To determine the efficacy of PD 0332991 in combination with 
cetuximab in incurable cetuximab -resistant  HPV -unrelated SCCHN.  Efficacy will be 
measured by the overall response rate (ORR=CR+PR) defined by RECIST criteria.  
4. Phase II, Arm 3: To determine the efficacy of PD 0332 991 in combination with 
cetuximab in incurable cetuximab -resistant HPV -related SCCHN.  Efficacy will be 
measured by the overall response rate (ORR=CR+PR) defined by RECIST criteria.  
 
2.2 Secondary Objectives  
 
1. Phase s I and  II, Arms 1 , 2, and 3 : To assess the adverse events of PD 0332991 in 
combination with cetuximab  
2. Phase II , Arms 1 , 2, and 3: To assess the progression -free survival (PFS) of patients 
with incurable SC CHN treated with PD 0332991 in combination with cetuximab  
3. Phase II , Arms 1 , 2, and 3: To asses s the overall survival (OS) of patients with incurable 
SCCHN treated with PD 0332991 in combination with cetuximab  
4. Phase II , Arms 1 , 2, and 3: To assess duration of response/stable disease of patients 
with incurable HPV -unrelated SC CHN treated with PD 0332 991 in combination with 
cetuximab  
 
2.3 Exploratory Objective s 
 
1. Phase II , Arms 1 and 2 : To document changes in p16 expression, Ki-67 (IHC) , 
phospho -Rb (IHC) , Cyclin D1 (IHC),  and apoptosis  (TUNEL assay)  after cetuximab 
and PD 0332991. Exploratory analysis will be performed to correlate these molecular 
changes with clinical endpoints (OR, TTP, PFS , and OS) .  RNA sequencing will also 
be performed.  
2. Phase II , Arms 1, 2, and 3 : To monitor quality of life as d ocumented by QOL 
measurements from the FACT H&N and EORTC QLQ -C30.  
 
 
3.0 PATIENT SEL ECTION  
 
3.1 Inclusion Criteria  
 
1. Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the 
head and neck.  
 
2. Disease must be considered incurable.  Incurable is defined as metastatic disease or a 
local or regional recurrence in a previously irradiated site that is unresectable (or patient 
declines resection).  
 
3. Measurable disease defined as lesions that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as >10 mm with CT scan, as >20 mm by 
Protocol Version:  Amendment 6; 10/24/17   Page 17 of 73 
 chest x -ray, or >10 mm with calipers by clinical exam.  (Phase I only : patients without 
measurable disease by RECIST 1.1 criteria but with evaluable disease by imaging or 
physical exam will be eligible as well.)  
 
4. Phase I only : any (or no) prior therapy for metastatic disease is allowed, including 
cetuximab .  If a patient has not received prior standard therapy, s/he must have been 
offered and refused prior standard therapy.  
 
5. Phase II only : 
Arm 1 : disease progression after at least one cycle of prior treatment with cisplatin or 
carboplatin  for incurable disease .  Prior treatment with cetuximab fo r incurable disease 
is not permitted.  
Arms 2 and 3 : disease progression after at least one cycle of treatment with cetuximab 
for incurable disease.  
 
6. Phase II only : at least one line of prior therapy for incurable disease.  
 
7. Phase II only : 
Arms 1 and 2 : disease must be determined to be HPV -unrelated .  HPV -unrelated 
SCCHN is defined as either p16 -negative OPSCC or non -OPSCC (larynx, 
hypopharynx, oral cavity) or p16 -negative unknown primary SCC presenting with a 
level 2 or 3 neck node.  p16 will be assessed  by IHC; a specimen showing any staining 
will be considered p16 -positive . 
Arm 3 : disease must be HPV -related SCCHN (defined as OPSCC or unknown 
primary presenting with a neck mass that is either p16 positive or HPV ISH or PCR 
positive).  
 
8. Minimum of 14 days  elapsed since the end of any prior therapy . 
 
9. At least  18 years  of age . 
 
10. Resolution of all acute toxic effects of prior anti -cancer therapy or surgical procedures 
to NCI CTCAE version 4.0 Grade ≤ 1 (except alopecia or other toxicities not 
considered a safety risk for the patient at investigator ’s discretion)  
 
11. ECOG performance status < 2 (see Appendix A). 
 
12. Adequate  bone marrow and organ function as defined below:  
a. Absolute neutrophil coun t > 1,500 mm3 
b. Platelets > 100,000 mm3 
c. Hemoglobin > 9 g/dL  
d. Total bilirubin  < 1.5 x IULN  except in the case of patients with Gilbert’s disease  
e. AST  (SGOT)  and ALT  (SGPT)  < 2.5 x IULN  for patients without liver metastases 
and ≤ 5.0 x IULN for patients with liver metastases  
f. Alkaline phosphatase ≤ 2.5 x IULN for patients wit hout bone metastases and ≤ 5.0 
x IULN for patients with bone metastases  
Protocol Version:  Amendment 6; 10/24/17   Page 18 of 73 
 g. Serum c reatinine ≤ 1.5 x IULN OR calculated c reatinine clearance  > 50 
mL/min/1.73 m2 for patients  with creatinine levels above institutional normal  
 
13. Baseline corrected QT interval (QTc ) < 480 ms.   
 
14. Women of childbearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control, abstinence) prior to study entry and for 
the duration of study participation.  Should a woman become pregnant  or suspect she 
is pregnant while participating in this study, she must  inform her treating physician 
immediately.  
 
15. Available archival tumor tissue for the proposed correlative studies.  
 
16. Ability to understand and willing ness to sign a n IRB approved  written informed 
consent document  (or that of legally authorized representative, if applicable) . 
 
3.2 Exclusion Criteria  
 
1. Phase II , Arm 1  only: prior treatment with cetuximab . 
 
2. A history of other malignancy ≤ 1 year previous with the exception of basal cell or 
squamous cell carcinoma of the skin which were treated with local resection only , 
carcinoma in situ  of the cervix , or synchronous H&N primaries . 
 
3. Currently r eceiving any other investigational agents.  
 
4. Patient must not have a history of or clinical evidence of central nervous system 
metastases or leptomeningeal carcinomatosis, except for individuals who have had 
previously -treated CNS metastases, are asymptomatic, and have had no requirement 
for steroids or anti-seizure medications (with the exception of Keppra) for 1 month 
prior to first dose of PD 0332991 . 
 
5. A history of allergic reactions attributed to compounds of similar chemical or biologic 
composition to PD 0332991, cetuximab, or other agents used in the study.  
 
6. Treated within the last 7 days prior to Day 1 of protocol therapy  with:  
a. Food or drugs that are known to be CYP3A4 inhibitors (e.g. grapefruit juice, 
verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, 
telithromycin, indinavir, ritonavir, nelfinavir, atazanavir, amprenavir, nefazodone, 
diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, 
progesterone, rifampin, phenobarbital, St. John’s wort).   (See Appendix D)  
b. Drugs that are kno wn to prolong the QT interval . 
c. Drugs that are proton pump inhibitors.   
 
7. Uncontrolled electrolyte disorders that can compound the effects of a QTc -prolonging 
drug (e .g., hypocalcemia, hypokalemia, hypomagnesemia)  
Protocol Version:  Amendment 6; 10/24/17   Page 19 of 73 
  
8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance with 
study requirements . 
 
9. Pregnant  and/or br eastfeeding.   Women of childbearing potential must have a negative 
serum pregnancy test within 28 days of study entry.  Female patients must be surgically 
sterile or be postmenopausal, or must agree to use effective contraceptive during the 
period of the t rial and for at least 90 days after completion of treatment. The decision 
of effective contraception will be based on the judgment of the principal investigator 
or a designated associate.  
 
10. Phase I and Arm 1 of Phase II : Known HIV-positiv ity and on combina tion antiretroviral 
therapy because of the potential for pharmacokinetic interactions with PD 0332991.  In 
addition, these patients are at increased risk of lethal infections when treated with 
marrow -suppressive therapy.  Appropriate studies will be undert aken in patients 
receiving combination antiretroviral  therapy when indicated.  
Arms 2 and 3 of Phase II : patients with HIV infection and antiretroviral therapy are not  
excluded, as there are no pharmacokinetic tests being performed.  
 
3.3 Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethnic group s are eligible for this trial.  
 
 
4.0 REGISTRATION PROCEDURES  
 
Patients must not start any protocol intervention  prior to registration through the Siteman 
Cancer Center.  
 
The following steps must be taken before registering patients to this study:  
 
1. Confirmation of patient eligibility  by Washington University  
2. Registration of patient in the Siteman Cancer Center OnCore database  
3. Assignment of unique patient number (UPN)  
 
Once the patient ha s been entered in the Siteman Cancer Center OnCore database, the WUSM 
coordinator will forward verification of enrollment and the UPN via email.  
 
4.1 Confirmation of Patient Eligibility  
 
Confirm patient eligibility by collecting  the information listed below  and scanning and 
emailing it to the research coordinator listed in the Siteman Cancer Center Clinical Trials 
Core Protocol Procedures for Secondary Sites  packet at least one business day prior to 
registering patient : 
Protocol Version:  Amendment 6; 10/24/17   Page 20 of 73 
  
1. Your name and contact information (te lephone number, fax number, and email 
address)  
2. Your site’s PI’s name, t he registering MD’s name , and your institution name  
3. Patient’s race, sex, and DOB  
4. Three letters (or two letters and a dash) for the patient’s initials  
5. Currently approved protocol version  date 
6. Copy of signed consent form  (patient name may be blacked out)  
7. Planned date of enrollment  
8. Completed eligibility checklist , signed and dated by a member of the study team  
9. Copy of appropriate source documentation  confirming patient eligibility  
 
4.2 Patient Registration in the Siteman Cancer Center OnCore Database  
 
Registrations may be submitted Monday through Friday between 8am and 5pm CT.  Urgent 
late afternoon or early morning enrollments should be planned in advance and coordinated 
with the Washington University research coordinator.  Registration will be confirmed by 
the research coordinator or his/her delegate by email within one business day.  Verification 
of eligibility and registration should be kept in the patient chart.  
 
All p atients  at all sites  must be registered through the Siteman Cancer Center  OnCore 
database at Washington University . 
 
4.3 Assignment of UPN  
 
Each patient will be identified with a unique patient number (UPN) for this study.  Patients 
will also be identified by first, middle, and l ast initials.  If the patient has no middle initial, 
a dash will be used on the case report forms (CRFs).  All data will be recorded with this 
identification number on the appropriate CRFs.  
 
 
 
5.0 TREATMENT PLAN  
 
5.1 Premedication for Cetuximab  
 
In an effort to prevent a hypersensitivity reaction, all patients should be premedicated with 
diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) IVPB given at least 
30 minutes prior to cetuximab.  Premedication may also include one liter of normal saline, 
hydrocortisone 100 mg IVPB, and /or albuterol inhalation (by nebulizer or inhaler) 
according to standard of care procedures.  
 
5.2 Agent Administration  
 
PD 0332991 should be taken by mouth on Days 1 through 21 of each 28 -day cycle.  
Patients sh ould take PD 0332991 capsules with food.   Patients will be required to keep 
Protocol Version:  Amendment 6; 10/24/17   Page 21 of 73 
 a drug diary (Appendix B).  
 
If a patient misses a day’s dose entirely, s/he must be instructed not to make it up the next 
day but to just take his/her regular dose the following da y.  If a patient vomits any time 
after taking a dose, s/he must be instructed not to make it up but to resume subsequent 
dosing the next day as prescribed.  If a patient inadvertently takes an extra dose during a 
day, s/he must be instructed to not take th e next day’s dose.  
 
Cetuximab will be administered intravenously on a weekly schedule.  The first dose of 
cetuximab will be 400 mg/m2; every week thereafter, patients will receive a dose of 250 
mg/m2.  Patients will continue to receive weekly cetuximab at 250 mg/m2 for the duration 
of their participation on study.  
 
Upon IRB/EC approval of Amendment 5, a PD 0332991  oral solution will be available for 
patients who cannot swallow the PD 332991  capsules. Patients who begin the study 
receiving the oral solution will remain on the oral solution for the duration of their time on 
treatment in the study.  Patients, who begin the study receiving capsules but develop 
difficulty swallowing the capsules and did not have disease progression, will be allowed to 
switch to the PD 0332991  oral solution.  These patients will then remain on the oral solution 
for the duration of their time on treatment in the study.  Each clinical site will be provided 
the oral so lution Investigational Product Manual (IPM) containing the dosage and 
administration instructions (DAI) for preparation of the PD 0332991  oral solution. Patients 
can take PD 0332991 oral solution with or without food .  
 
5.3 Re-Treatment Criteria  
 
A new cycle of treatment with PD 0332991 may begin only if:  
 ANC ≥1,000 /mcL. 
 Platelets count ≥50,000/ mcL. 
 Non-hematologic toxicities have returned to baseline or no greater than g rade 1 (or 
no greater than grade 2  if not considered a safety r isk for the patient  (at the  
investigator’s discretion) ). 
 
If these conditions are not met , treatmen t with  PD 0332991 must be delayed by one week. 
If, after a one-week delay, all toxicities have  recovered within the limits described above, 
treatment with PD 0332991 can be resumed.  
 
If the patient has not recovered after 2 weeks (including the scheduled 1 -week off treatment  
period within a cycle), treatment with PD 0332991 will be permanently discontinued .  
  
Protocol Version:  Amendment 6; 10/24/17   Page 22 of 73 
  
5.4 Dose Escalation Schema  for Phase I  
 
Dose Escalation Schedule (for the Phase I portion ) 
Dose Level  PD 0332991  Dose*  Cetuximab Dose  
Level -1 75 mg  Loading dose : 400 mg/m2 
Weekly thereafter : 250 mg/m2 for 
the duration of study participation  Level 1 (Starting Dose)  100 mg  
Level 2  125 mg  
 
* PD 0332991 is administered on Days 1 through 21 of each 28 -day cycle.  
 
Dose escalation will not occur until all patients in the cohort have completed the first cycle 
and the Principal Investigator has been able to review all toxicities.  
 
5.5 Definition of MTD, DLT, Dose Escalation Criteria , and Toxicity, Response, 
and DLT Evaluations  for Phase I  
 
5.5.1 Definition of Max imum Tolerated Dose (MTD)  
 
The maximum tolerated dose (MTD) is defined as the dose level immediately 
below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience 
dose-limiting toxicity during the first cycle.  Dose escalations will proceed until the 
MTD has been reached.  
 
5.5.2 Dose Limiting Toxicities (DLTs)  
 
Hematologic DLT is defined as any of the following that occur during the first cycle 
that are attribu ted as possibly, probably , or definitely related to the study treatment:  
 
 grade 4 neutropenia ≥ 7 day duration  
 grade 4 infection with grade 3 or 4 neutropenia  
 grade 4 thrombocytopenia associated with life -threatening bleeding  
 treatment held for > 14 days d ue to hematologic toxicity  
 febrile neutropenia of any duration with temperature > 38.5 °C  
 
Non-hematologic DLT is defined as any possibly, probably, or definitely related 
grade 3 or grade 4 non -hematologic toxicity that occurs during the first cycle with 
the following specific exceptions:  
 
 suboptimally treated grade 3 or 4 nausea, vomiting, diarrhea, anorexia , or 
lymphopenia  
 grade 3 metabolic abnormalities  (specifically limited to potassium, 
magnesium and calcium)  
 any hypersensitivity / infusion reaction o r acneiform rash due to cetuximab  
 treatment held for > 14 days due to non -hematologic toxicity  
 
Protocol Version:  Amendment 6; 10/24/17   Page 23 of 73 
 5.5.3 Dose Escalation Criteria  
 
Dose escalations will proceed as follows after the occurrence of dose -limiting 
toxicity (DLT):  
 
Number of Patients 
with DLT at a Given  
Dose Level  Escalation Decision Rule  
0 out of 3  Enter 3 patients at the next dose level.  
>2 Dose escalation will be stopped.  Three (3) additional 
patients will be entered at the next lowest dose level if 
only 3 patients were treated previously at that dose.  
1 out of 3  Enter at least 3 more patients at this dose level.  
 
If 0 of these 3 patients experience DLT, proceed to the 
next dose level.  
 
If 1 or more of this group suffer DLT, then dose 
escalation is stopped.  Three (3) additional patients will 
be entered at the next lowest dose level if only 3 
patients were treated previously at that dose.  
<1 out of 6 at highest 
dose level below the 
maximally 
administered dose  This is generally the recommended phase 2 dose. At 
least 6 patients must be entered at t he recommended 
phase 2 dose.  
 
5.5.4 Toxicity, Response, and DLT Evaluations  
 
All patients who receive any study treatment are evaluable for toxicity.  Patients 
are evaluated from first receiving study treatment until a 30 -day follow up after the 
conclusion of t reatment or death.  
 
All patients are evaluable for disease response unless they come off study due to 
treatment related adverse events(s) prior to completion of Cycle 2 and have not had 
any disease assessment.  
 
A patient is evaluable for DLT assessment onl y during Cycle 1  of treatment  and 
only if enrolled in phase I of the tr ial.  If the patient is not able to be treated on Day 
1 of Cycle 2 , then s/he is  still considered in Cycle 1 active treatment and can 
experience  a DLT.  Once the patient has been treate d in Cycle 2, s/he will no longer 
be evaluated for DLTs in all subsequent cycles.  
 
5.6 Dosing for Phase II  
 
Dosing for phase II will be administered as per Section 5.2.  Dose of PD 0332991 will be 
125 mg , which was the highest dose given in phase I (no MTD found) .  Thirty patients will 
Protocol Version:  Amendment 6; 10/24/17   Page 24 of 73 
 be enrolled to Arm 1 of phase II, 30 patients will be enrolled to Arm 2 of phase II , and 24 
patients will be enrolled to Arm 3 of phase II .  Enrollment for all arms may take place 
concurrently.  
 
5.7 General Concomitant Medication and Supportive Care Guidelines  
 
While taking PD 0332991, patients should be instructed to avoid food or drugs that are 
known strong CYP3A4 inhibitors or inducers.   Patients should also refrain from the use of 
proton pump inhibitors; if needed, alternative antacid therapies may be used including H2 -
receptor antagonists, and locally acting antacids.  H2 -receptor antagonists should be 
administered with a staggered dosing regimen (twice daily).  The dosing of PD 0332991 
should occur at least 10 hours after the H2-receptor antagonist dose and 2 hours before the 
H2-receptor antagonist morning dose.  Local antacid should be given at least 2 hours before 
or 2 hours after PD 0332991 administration.  
 
Patients should receive full supportive care during the study, inclu ding transfusion of blood 
and blood products and treatment with antibiotics, analgesics, erythropoietin, or 
bisphosphonates when appropriate.  
 
Anti-emetics (such as prochlorperazine, lorazepam, ondansetron, or other 5 -HT3 
antagonists) may be administered p rophylactically in the event of nausea.  Anti -diarrheals, 
such as loperamide, may be administered as ne eded in the event of diarrhea.  
 
5.8 Women of Childbearing Potential  
 
Women of child bearing potential ( defined as women with regular menses , women  with 
amenor rhea, women with irregular cycles, women using a contraceptive method that 
precludes withdrawal bleeding , and w omen who have had a tubal ligation ) are required to 
have a negative serum pregnancy test within 28 days prior to the first dose of  study 
treatmen t.   
 
Female and male patients (along with their female partners) are required to use two forms 
of acceptable contraception, including one barrier method, during participation in the study 
and for 3 months following the last dose of  PD 0332991 .  
 
If a patient is suspected to be pregnant, all study drugs should be immediately discontinued.  
In addition a positive urine test must be confirmed by a serum pregnancy test.  If it is 
confirmed that the patient is not pregnant, the patient may resume dosin g. 
 
If a female patient or female partner of a male patient becomes pregnant during therapy or 
within 28 days after the last dose of  either study drug , the investigator must be notified in 
order to facilitate outcome follow -up. 
 
5.9 Duration of Therapy  
 
If at any time the constraints of this protocol are considered to be detrimental to the 
Protocol Version:  Amendment 6; 10/24/17   Page 25 of 73 
 patient’s health and/or the patient no longer wishes to c ontinue protocol therapy, the 
protocol therapy should be discontinued and the reason(s) for discontinuation documente d 
in the case report forms.  
 
In the absence of treatment delays due to adverse events, treatment may continue 
indefinitely until one of the following criteria applies:  
 
 Documented and confirmed disease progression  
 Death  
 Adverse event(s) that, in the judgme nt of the investigator, may cause severe or 
permanent harm or which rule out continuation of study drug  
 General or specific changes in the patient’s condition render the patient 
unacceptable  for further treatment in the judgment  of the investigator  
 Suspect ed pregnancy  
 Serious non -compliance with the study protocol  
 Lost to follow -up 
 Patient withdraws consent  
 Investigator removes the patient from study  
 The Siteman Cancer Center decides to close the study  
 
Patients who prematurely discontinue treatment for any  reason will be followed as 
indicated in the study calendar . 
 
5.10 Duration of Follow -up 
 
Patients will be followed every 2 months for 5 years  or until death, whichever occurs first.  
Patients removed from study for unacceptable adverse events will be followed until 
resolution  or stabilization of the adverse event.  
 
 
6.0 DOSE DELAYS/DOSE MODIFICATIONS  
 
6.1 Dose Modifications for PD 0332991  
 
Patients will  be monitored for toxicity and the dose of PD 0332991 may be adjusted as  
indicated in the table below .  Dose reduction by 1, and if possible, 2 dose levels will be 
allowed depending on the type and severity of toxicity encountered.   Patients requiring 
more  than 2 dose reductions will be discontinued from the study.  
 
Recommended dose reductions for PD 0332991 are  to decrease the current dose by 25 mg.  
The lowest dose available is 75 mg.  Doses may be held  as needed for toxicity resolution 
during a cycle. Dos es omitted for toxicity are not replaced  or restored within the same cycle  
(meaning that the cycle remains 28 days regardless of the number of doses of taken) . 
 
If a patient experiences a toxicity which has not resolved to grade 2 or lower within two 
weeks  (inclusive of the scheduled off -week), t reatment with PD 0332991 should be 
Protocol Version:  Amendment 6; 10/24/17   Page 26 of 73 
 permanently discontinued.   
 
PD 0332991 Dose Modifications Based on Worst Treatment -Related Toxicity in the 
Previous Cycle  
Worst Toxicity During Previous Cycle  New Dose Level  
Grade  4 neutropenia  Decrease by one dose level  
Grade 4 thrombocytopenia  Decrease by one dose level  
Grade 3 neutropenia associated with a documented 
infection or fever > 38.5 ºC  Decrease by one dose level  
Grade > 3 non -hematologic toxicity (includes nausea, 
vomiting, diarrhea, and hypertension only if 
persisting despite maximal medical treatment)  Decrease by one dose level  
Delay by > 1 week in receiving the next scheduled 
dose due to persisting treatment -related toxicities  If recovery occurs within 2 
weeks, continue and decrease 
by one dose level  
Inability to deliver at least 80% of the planned dose of 
PD 0332991 due to adverse events possibly related to 
study treatment  Decrease by one dose level  
 
6.1.1 Dose Adjustmen ts Due to QTc Prolongation  
 
Any patients who develops new grade 2 or greater ECG QT corrected interval 
prolonged at any time during the study will need to have the ECG repeated 
immediately for confirmation.  
 
Grade 2 : no adjustments; continue at same dose level  
Grade 3 (reversible cause identified and corrected) : withhold treatment until QTc 
< 470 msec, then resume treatment at the same dose level  
Grade 3 (no reversible cause identified) : withhold treatment until QTc < 470 msec, 
then decrease PD 0332991 by one dose level  
Grade 4 : permanently discontinue PD 0332991  
 
6.2 Dose Modifications or Delays for Cetuximab  
 
6.2.1 Dermatologic Adverse Effects  
 
Patients developing dermatologic toxicities while receiving cetuximab should be 
monitored for the development of inflammat ory or infectious sequelae, and 
appropriate treatment of these symptoms initiated.  Dose modifications of any 
future cetuximab infusions should be instituted in case of severe (grade 3) 
acneiform rash.  Treatment with topical and/or oral antibiotics (minoc ycline 100 
mg bid) should be considered; topical corticosteroids are not recommended.  
 
If a patient experiences severe acneiform rash, cetuximab treatment adjustments 
should be made according to the following table.  In patients with mild and 
moderate skin  toxicity, treatment should continue without dose modification.  
Protocol Version:  Amendment 6; 10/24/17   Page 27 of 73 
  
Cetuximab Dose Modification Guidelines  
Grade 3  
Acneiform  Rash  Cetuximab  Outcome  Cetuximab Dose 
Modification  
1st occurrence  Delay infusion 1 -2 
weeks  Improvement  Continue at 250 mg/m2 
  No Improvement  Discontinue cetuximab  
2nd occurrence  Delay infusion 1 -2 
weeks  Improvement  Reduce Dose Level -1 
  No Improvement  Discontinue cetuximab  
3rd occurrence  Delay infusion 1 -2 
weeks  Improvement  Reduce to Dose Level -2 
  No Improvement  Discontinue cetuximab  
4th occurrence  Discontinue cetuximab  
 
Cetuximab Dose Levels*  
Starting dose  250 mg/m2 
Dose Level –1 200 mg/m2 
Dose Level –2 150 mg/m2 
 
*There will be no dose level reductions below a weekly dose of 150  mg/m2.   
 
6.2.2 Gastrointestinal Adverse Effects  
 
Antiemetic agents may be administered prior to the administration of cetuximab.  
Diarrhea will be treated symptomatically with antidiarrheal agents.  Should GI 
toxicity become severe enough to require hospitalization or outpatient IV fluid 
replace ment, all treatment should be discontinued temporarily until the patient’s 
condition improves.  
 
6.2.3 Management of Hypersensitivity Reactions  
 
Mild (grade 1) hypersensitivity reactions (HSRs) characterized by mild pruritus, 
flushing, rhinitis, rash, and fever  are treated with symptom -directed management , 
including cessation of infusion, administration of diphenhydramine 25 mg IVP 
(may repeat x2).  Vital signs should be monitored every 15 minutes until symptoms 
resolve.  Treatment may be restarted at the same r ate at resolution of symptoms.  
 
Moderate (grade 2) HSRs consist of generalized pruritus, flushing, rash, back pain, 
dyspnea, hypotension , and rigors . The infusion should be stopped, and oxygen 
should be administered if the patient is experiencing dyspnea.  Normal saline 500 
Protocol Version:  Amendment 6; 10/24/17   Page 28 of 73 
 mL bolus may be given if the patient is hypotensive (may repeat as needed).  
Diphenhydramine 50 mg IVP should be administered, followed by hydrocortisone 
100 mg IVP followed by meperidine 25 mg IV (for rigors).  Vital signs should be 
monitored every 2 minutes until stable, then every 15 minutes until symptoms 
resolve.  Treatment may be restarted at resolution of symptoms as follows: 8 hour 
rate for 5 minutes, then 4 hour rate for 5 minutes, the 2 hour rate for 5 minutes until 
the original  rate of infusion is reached.  
 
Severe (grade 3) HSRs are characterized by bronchospasm, generalized urticaria, 
hypotension, and  angioedema.   These HSRs should be managed by stopping the 
infusion  and administering: normal saline 500 mL bolus (repeat as need ed), 
epinephrine (1:1000) 0.3 mg IM, diphenhydramine 50 mg IVP, hydrocortisone 100 
mg IVP, and albuterol 2.5 mg inhalation (for bronchospasms).  Vital signs should 
be monitored every 2 minutes until stable, then every 15 minutes until symptoms 
resolve.  If  cetuximab is restarted, restart the infusion rate at 25% of original rate 
for 30 minutes, then increase to 50% of infusion rate for the remainder of the 
infusion.  The infusion rate should be permanently reduced by 50%.  
 
Life-threatening/disabling (grade 4) HSRs consist of anaphylaxis, airway 
obstruction, shock, cardiac arrest, or prolonged hypotension.  
 
Grade 4 HSRs require the immediate interruption of cetuximab therapy and 
permanent discontinuation from further treatment  with cetuximab .  Appropriate 
medical therapy including epinephrine, corticosteroids, intravenous antihistamines, 
bronchodilators, and oxygen should be available for use in the treatment of such 
reactions.  Patients should be carefully observed until the complete resolution of all 
signs a nd symptoms.  
 
6.2.4 Infusion Reaction Adverse Effects  
 
Severe infusion reactions (Grade 4) require the immediate interruption of 
cetuximab therapy and permanent discontinuation from further treatment.  
Appropriate medical therapy including epinephrine, corticost eroids, intravenous 
antihistamines, bronchodilators, and oxygen should be available for use in the 
treatment of such reactions.  Patients should be carefully observed until the 
complete resolution of all signs and symptoms.  
 
In prior clinical trials, mild to moderate infusion reactions were managed by 
slowing the infusion rate of cetuximab and by continued use of antihistamine pre -
medications (e.g., diphenhydramine) in subsequent doses.  If the patient 
experiences a moderate (Grade 3) infusion reaction, the  infusion rate should be 
permanently reduced by 50%.  For grade 1 or 2 reactions, additional doses of 
diphenhydramine or corticosteroids may be administered.  
  
Protocol Version:  Amendment 6; 10/24/17   Page 29 of 73 
  
6.2.5 Drug Fever Adverse Effects  
 
If a patient experiences isolated drug fever, subsequent pre -treatment with 
acetaminophen or a non -steroidal anti -inflammatory agent may be considered. If a 
patient experiences recurrent isolated drug fever following premedication and post -
dosing with an a ppropriate antipyretic, the infusion rate for subsequent dosing 
should be 50% of previous rate.  
 
6.2.6 Pulmonary Adverse Effects  
 
In the event of acute onset (grade ≥ 2) or worsening pulmonary symptoms which 
are not thought to be related to underlying cancer, cetuximab therapy should be 
interrupted and a prompt investigation of these symptoms should occur. Cetuximab 
retreatment shoul d not occur until these symptoms have resolved to grade 1.  If 
interstitial lung disease is confirmed, cetuximab should be discontinued and the 
patient should be treated appropriately.  
 
6.2.7 Renal Adverse Effects  
 
Hypomagnesemia has been reported with cetuxima b when administered as a single 
agent and in combination with multiple different chemotherapeutic regimens. 
Patients receiving cetuximab should be monitored for hypomagnesemia. 
Magnesium repletion may be necessary based on clinical judgment.  
 
 
7.0 REGULATORY A ND REPORTING REQUIREMENTS  
 
The entities providing oversight of safety and compliance with the protocol require reporting as 
outlined below.  
 
The Washington University Human Research Protection Office (HRPO) requires that all events 
meeting the definition o f unanticipated problem or serious noncompliance be reported as outlined 
in Section 7.2.  
 
The FDA requires that all serious and unexpected adverse events be reported as outlined in Section 
7.6. In addition, any fatal or life -threatening adverse experiences  where there is a reasonable 
possibility of relationship to study intervention must be reported.  
 
Pfizer requires that adverse events be reported as outlined in Section 7.7.  
 
7.1 Definitions  
 
7.1.1 Adverse E vents (AEs)  
 
Definition:  any unfavorable medical occurrence in a human subject including any 
Protocol Version:  Amendment 6; 10/24/17   Page 30 of 73 
 abnormal sign, symptom, or disease.  
 
Grading:  the descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4 .0 will be utili zed for 
all toxicity reporting .  A copy of the CTCAE version 4 .0 can be downloaded from 
the CTEP website.  
 
Attribution (relatedness), Expectedness, and Seriousness:  the definitions for the 
terms listed that should be used are those provided by the Departme nt of Health 
and Human Services’ Office for Human Research Protections (OHRP).  A copy of 
this guidance can be found on OHRP’s website:  
http://www.hhs.gov/ohrp/policy/advevntguid.html  
 
7.1.2 Serious  Adverse Event (SAE)  
 
Definition:  any adverse drug experience occurring at any dose that results in any 
of the following outcomes:  
o Death  
o A life -threatening adverse drug experience  
o Inpatient hospitalization or prolongation of existing hospitalization  
o A persistent or significant disability/incapacity (i.e., a substantial disruption 
of a person’s ability to conduct normal life functions)  
o A congenital anomaly/birth defect  
o Any other experience which, based upon appropriate medical judgment, 
may jeopardize th e subject and may require medical or surgical intervention 
to prevent one of the outcomes listed above  
 
All unexpected SAEs must be reported to the FDA.  
 
7.1.3 Unexpected Adverse Experience  
 
Definition:  any adverse drug experience, the specificity or severity of  which is not 
consistent with the current investigator brochure (or risk information, if an IB is not 
required or available).  
 
Events that are both serious AND unexpected must be reported to the FDA.  
7.1.4 Life-Threatening Adverse Experience  
 
Definition:  any a dverse drug experience that places the subject (in the view of the 
investigator) at immediate risk of death from the reaction as it occurred, i.e., it does 
not include a reaction that, had it  occurred in a more severe form, might have caused 
death.  
 
Life-threatening adverse experiences must be reported to the FDA.  
  
Protocol Version:  Amendment 6; 10/24/17   Page 31 of 73 
  
7.1.5 Unanticipated P roblem s 
 
Definition:  
 
 unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol -related documents, such a s the 
IRB-approved research protocol and informed consent document; and (b) the 
characteristics of the subject population being studied;  
 related or possibly related to participation in the research ( “possibly related ” 
means there is a reasonable possibilit y that the incident, experience, or outcome 
may have been caused by the procedures involved in the research); and  
 suggests that the research places subjects or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) t han was 
previously known or recognized.  
 
7.1.6 Noncompliance  
 
Definition:  failure to follow any applicable regulation or institutional policies that 
govern human subjects research or failure to follow the determinations of the 
IRB.   Noncompliance may occur due to lack of knowledge or due to deliberate 
choice to ignore regulatio ns, institutional policies, or determinations of the IRB.  
 
7.1.7 Serious N oncompliance  
 
Definition:  noncompliance that materially increases risks, that results in substantial 
harm to subjects or others, or that materially compromises the rights or welfare of 
participants.  
 
7.1.8 Protocol Exceptions  
 
Definition:  A planned deviation from the approved protocol t hat are under the 
research team’s control. Exceptions apply only to a single participant or a singular 
situation.  
 
Local IRB p re-approval of all protocol exceptions must be obtained prior to the 
event.   For secondary sites, the Washington University PI wil l issue approval of the 
exception, but it must also be submitted to the local IRB with documentation of 
approval forwarded to Washington University.  HRPO approval is not required for 
protocol exceptions occurring at secondary sites.  
 
7.2 Reporting to the Huma n Research Protection Office (HRPO) at Washington 
University  
 
The PI is required to promptly notify the IRB of the following events:  
 
Protocol Version:  Amendment 6; 10/24/17   Page 32 of 73 
  Any unanticipated problems involving risks to participants or others which occur 
at WU, any BJH or SLCH institution, or th at impacts participants or the conduct of 
the study.  
 Noncompliance with federal regulations or the requirements or determinations of 
the IRB.  
 Receipt of new information that may impact the willingness of participants to 
participate or continue participatio n in the research study.  
 
These events must be reported to the IRB within 10 working days  of the occurrence of the 
event or notification to the PI of the event.   The death of a research participant that qualifies 
as a reportable event should be reported wi thin 1 working day  of the occurrence of the 
event or notification to the PI of the event.  
 
7.3 Reporting to the Quality Assurance and Safety Monitoring Committee 
(QASMC) at Washington University  
 
The PI is required to notify the QASMC of any unanticipated problem occurring at WU or 
any BJH or SLCH institution that has been reported to and acknowledged by HRPO as 
reportable.  (Unanticipated problems reported to HRPO and withdrawn during the review 
process need not be reported to QASMC.)  
 
QASMC must be notifi ed within 10 days  of receipt of IRB acknowledgment via email to 
a QASMC auditor.  
 
7.4 Reporting Requirements for Secondary Sites  
 
The research team at each secondary site is required to promptly notify the Washington 
University PI and research coordinator of a ll reportable events (as described in Section 7.6) 
within 1 working day  of the occurrence of the event or notification of the secondary site’s 
PI of the event.  This notification may take place via email if there is not yet enough 
information for a formal written report (using either an FDA MedWatch form if required 
or an ins titutional SAE reporting form if not).  A formal written report must be sent to the 
Washington University PI and research coordinator within 10 working days  of the 
occurrence of the event or notification of the secondary site’s PI of the event.  The death 
of a research participant that qualifies as a reportable event should be reported within 1 
working day  of the occurrence of the event or notification of the secondary site’s PI of the 
event.  
 
The research team at a secondary site is responsible for followi ng its site’s guidelines for 
reporting applicable events to its site’s IRB according to its own institutional guidelines.  
The research team at Washington University is responsible for reporting all applicable 
events to the FDA.  
 
7.5 Reporting to Secondary Sit es 
 
The Washington University PI (or designee) will notify the research team at each secondary 
Protocol Version:  Amendment 6; 10/24/17   Page 33 of 73 
 site of all reportable events that have occurred at other sites within 10 working days  of the 
occurrence of the event or notification of the PI of the event.  Th is includes events that take 
place both at Washington University and at other secondary sites, if applicable.  
 
7.6 Reporting to the FDA  
 
The conduct of the study will comply with all FDA safety reporting requirements.  
PLEASE NOTE THAT REPORTING REQUIREMENTS FOR THE FDA DIFFER 
FROM REPORTING REQUIREMENTS FOR HRPO/QASMC.  It is the 
responsibility of the  Washington University principal  investigator to report any 
unanticipated problem to the FDA as follows:  
 
 Report  any unex pected fatal or life -threatening adverse experiences (Section 7.1.4) 
associated with use of the drug (i.e., there is a reasonable possibility that the 
experience may have been caused by the drug) by telephone or fax no later than 7 
calendar days  after init ial receipt of the information.  
 Report any serious, unexpected adverse experiences  (Section 7.1.2) , as well as 
results from animal studies that suggest significant clinical risk within 15 
calendar days  after initial receipt of this information .   
 
All MedW atch forms will be sent by the investigator or investigator’s team to the FDA at 
the following address or by fax:  
 
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Oncology Drug Products  
5901 -B Ammendale Rd.  
Beltsville, MD 2 0705 -1266  
FAX: 1 -800-FDA -0178  
 
Secondary sites must submit a completed MedWatch form to the Washington University 
PI and research coordinator within 4 calendar days  (for fatal or life -threatening adverse 
experiences) or 11 calendar days  (for serious, unexp ected adverse experiences).  The 
Washington University PI will be responsible for submitting all MedWatch forms from 
secondary sites to the FDA within the timeframes specified above.  
 
7.7 Reporting to Pfizer  
 
Within 24 hours of first awareness of the event (immediately if the event is fatal or life -
threatening), the PI or designee will report to Pfizer by facsimile any serious adverse drug 
experience (as defined in Section 7.7) that occurs during the SAE reporting period (as 
defined in Section 7. 9) in a stud y subject receiv ing PD 0332991.  Such SAEs will be 
reported using MedWatch form and the Pfizer Reportable Event Fax Cover Sheet 
(Appendix C) should also be included.  SAEs should be reported as soon as they are 
determined to meet the definition, even if complete information is not yet available.  
 
Protocol Version:  Amendment 6; 10/24/17   Page 34 of 73 
 Even though there may not be an associated SAE, exposure to PD 0332991 during 
pregnancy or lactation is reportable.   In addition, occupational exposure to PD 0332991 is 
reportable, and a lack of effect of PD 0332 991 may also be reportable.  
 
Hy’s Law Cases : Cases of potential drug -induced liver injury as assessed by laboratory test 
values (“Hy’s Law Cases”) are also reportable to Pfizer.  If a study subject develops 
abnormal values in aspartate transaminase (AST) o r alanine transaminase (ALT) or both, 
concurrent with abnormal elevations in total bilirubin and no other known cause of liver 
injury, that event would be classified as a Hy’s Law Case.  
 
7.8 Timeframe for Reporting Required E vents  
 
Adverse  events will be tra cked for 30 days following the last day of study treatment.  
 
 
8.0 PHARMACEUTICAL INFORMATION  
 
8.1 PD 0332991 (Palbociclib)   
 
8.1.1 PD 0332991  Description  
 
Laboratory Code: PD 0332991 -00 
Molecular Weight: 447.54  
Molecular Formula: C 24H29N7O2 
 
Formulation s: 
Capsule:  
PD-0332991 -00 capsules will be provided as the active ingredient with precedented 
excipients filled in hard gelatin capsules composed of gelatin and precedented 
colorants.   These formulations will be packaged in appropriate packaging material 
and should be  stored in line with labeled storage conditions.  
 
Oral Solution : 
PD-0332991 -00 will be provided and/or dosed as an oral solution using precedented 
excipients with appropriate packaging and storage conditions.   
 
8.1.2 Clinical Pharmacology  
 
PD 0332991 is a highly  selective inhibitor of Cdk4/cyclinD 1 kinase activity (IC 50 = 
11 nM;  Ki = 2 nM). PD 0332991 has selectivity for Cdk4/6, with little or no activity  
against a large panel of 34 other protein kinases including other Cdks and a wide 
variety of  tyrosine and ser ine/threonine kinases. Cdk6, another enzyme that also 
complexes with  cyclin -D subunits, is also commonly expressed in mammalian cells 
and tumors. Cdk6 is  highly homologous to Cdk4 and can perform the same function 
by phosphorylating Rb, thus  potentially cr eating a redundant mechanism to 
promote cell cycle progression.  Consequently, inhibition of both enzymes is 
Protocol Version:  Amendment 6; 10/24/17   Page 35 of 73 
 necessary to ensure complete suppression of Rb  phosphorylation and the greatest 
possible spectrum of antitumor activity. Results indicate  that PD 03 32991 inhibits 
Cdk6 with equivalent potency to Cdk4.  
 
8.1.3 Pharmacokinetics and Drug Metabolism  
 
To date pharmacokinetic data have been reported  for four studies (A5481001, 
A5481002,  A5481003 and A5481004). Final PK data are available from studies 
A5481001 and  A5481002.   Pharmacokinetic parameters are available from all 74 
patients enrolled in Protocol A5481001  following a single -dose (Day 1 of Cycle 1), 
and from 51 patients following multiple -dose administration (Day 8 of Cycle 1) of 
daily doses ranging from 25  to 225 mg of PD 0332991  (Table 4.). On Day 1, all 
patients had detectable plasma concentrations of PD 0332991 at the first  measured 
time point (1 hour) following oral administration. The exposure (AUC (0-10) and 
Cmax) increased in a dose -proportional manne r over the dose range of 25 -225 mg 
QD following PD 0332991 administration on Days 1 and 8 of Cycle 1, although 
some variability  (low to moderate) around these doses was observed particularly at 
the 150 mg QD dose level.  
 
 
Steady -state PK parameters are  available  for nine patients on Day 14 of Cycle 1 
(receiving 200 mg SC 0332991 QD for  2 weeks) and four patients on Day 21 of 
Cycle 1 ( receiving 125 mg QD for  3 weeks).   PD 0332991 was absorbed with a 
median Tmax of ~4 hours. The mean  PD 0332991 Vz/F was 3 103 L, which is 
 
Protocol Version:  Amendment 6; 10/24/17   Page 36 of 73 
 significantly greater than total body water (42 L),  indicating that PD 0332991 
extensively penetrates into peripheral tissues. PD 0332991 was eliminated slowly; 
the mean elimination half -life (t½) was 26.5 hours and the mean CL/F was 86.1 
L/hour. PD 0332991 accumulated following repeated dosing with a median Rac of 
2.4, which is consistent with the elimination half -life.  
 
 
 
Renal excretion of PD 0332991 was a minor route of elimination with ~1.7% of the 
drug excreted unchanged in urine over the 10 -hour collection period in the 125 mg 
and 200 mg  dose group, combined. The mean renal clearance (CLR) was 6.59 
L/hour.   
 
An exploratory evaluation of the circulating metabolites for PD 0332991 was 
conducted in  plasma samples obtained from patien ts tre ated with PD 0332991 200 
mg QD . Preliminary assessment of the pooled plasma samples on Day 14 of  Cycle 
1 indicated that the glucuronide conjugate of PD 0332991 and the lactam of  PD 
0332991 were the main metabolites present in plasma. Other metabolite s observed 
were  the glucuronide conjugates of hydroxylated PD 0332991 and the glucuronide 
conjugate of  reduced PD 0332991.  
  
The preliminary results from the recently performed food -effect study (“A5481021, 
a Phase 1, open -label 4 sequence 4 period crossov er study of palbociclib (PD -
0332991) in healthy volunteers to estimate the effect of food on the bioavailability 
of palbociclib”) has provided evidence that when a single 125 mg dose of 
palbociclib was administered under fed conditions (including high fat or low fat 
meal given together with palbociclib, or moderate fat meal given 1 hour before and 
2 hours after palbociclib) as a freebase capsule formulation the palbociclib exposure 
levels were more uniform across the population than when taken in the fastin g 
condition.  
 
Drug -drug interaction between PD 0332991 and letrozole was evaluated during  the 
 
Protocol Version:  Amendment 6; 10/24/17   Page 37 of 73 
 Phase 1 portion of  a breast cancer  study (A5481003 The  preliminary  data indicate 
a lack of a potential for drug -drug interaction  between PD 0332991 and letrozole 
when administered in combination.  
 
In a study in healthy subjects (Study A5481079), a PD 0332991 oral solution 
administered under fasted conditions and fed conditions (moderate fat, standard 
calorie meal) was bioequivalent to the commercial free base capsu le formulation of 
PD 0332991 given under fed conditions.  Additionally, the PD 0332991 oral 
solution administered under fasted conditions was bioequivalent to PD 0332991 
oral solution administered under fed conditions, suggesting that the PD 0332991 
oral s olution formulation can be given without regards to food intake. Additional 
information may be found in the IB for PD 0332991.  
 
8.1.4 Supplier(s)  
 
Pfizer will supply the study agent.  The study agent will be free of charge to the 
patient.  
  
8.1.5 Dosage Form and Preparation  
 
PD 0332991 Capsules  
PD 0332991 will be supplied as capsules containing 75  mg, 100  mg, or 125  mg 
equivalents of PD 0332991 free base.  The sponsor will supply the oral drug 
formulation to sites in high -density polyethylene (HDPE) bottles contai ning 
75 mg, 100  mg, or 125  mg capsules.  The capsules can be differentiated by their 
size and color, as shown in  the table below Error! Reference source not found. .  
Labeling will occur a ccording to local regulatory requirements.  
 
PD 0332991 Capsule Characteristics  
Strength  Capsule color  
75 mg  Sunset Yellow  
100 mg  Caramel/Sunset Yellow  
125 mg  Caramel  
 
The patient numb er and the protocol numb er should be recorded on the bottle  
label in the spaces provided. Site personn el must  ensure that patients clearly 
understand the directions  for self-medication. Patients should be  given a sufficient 
supp ly to last until their next study visit.  Unused drug and/or empty bottles should  
be returned to the site at the next study visit.  Returned, unused medication 
MUST NOT be re -dispensed to the patient.  
 
PD 0332991  is an agent that must  be handled and administ ered with care. 
Patients should  be inst ructed to keep their medication in the bottles provided 
and not transfer it to any other container. Due to possible  unkno wn hazards 
associated with topical and environmental exposu re to experimental agents, 
capsules must  not be opened and/or  emptied into any vehicle for oral ingestion;  
Protocol Version:  Amendment 6; 10/24/17   Page 38 of 73 
 capsules must  be swallowed intact. 
 
Only one capsule strength will be dispensed to the patient at each dispensing visit.  
In the event of dose modification, request should be made of the patient to return 
all previously dispensed medication to the clinic and new capsules will  be 
dispensed.  
 
PD 0332991 Oral Solution  
PD 0332991 oral solution (25 mg/mL) will be supplied in HDPE packaged bottles 
with a PIBA (push in bottle adapter) and a reusable oral syringe for dosing.  
Labeling will occur according to local regulatory requirements.  Each clinical site 
will be provided the oral solution IPM which contains the detailed dosage and 
administration instructions for preparation of the PD 0332991 oral solution.  The 
oral solution should be prepared and dispensed by an appropriately qualified and 
experienced member of the study staff (eg, physician, nurse, physician’s assistant, 
or pharmacist) as allowed by local, state, and institutional guidance.  
 
The patient number should be recorded on the bottle label in the spaces provided 
by site personnel at the time of assignment to patient.  Site personnel must ensure 
that patients clearly understand the directions for self -medication.  Patients should 
be given a sufficient supply to last until their next study visit.  Unused dr ug and/or 
empty bottles should be returned to the site at the next study visit.  Returned, 
unused medication MUST NOT be re -dispensed to the patient.  
 
PD 0332991 oral solution is an agent that must be handled and administered with 
care.  Patients should b e instructed to keep their medication in the bottles provided 
and not transfer it to any other container.  
 
8.1.6 Storage and Stability  
 
PD 0332991 capsules should be stored at controlled room temperature (15 -25°C, 
59-77°F) in their original container. PD 0332991  oral solution should be stored in 
its original container and in accordance with the conditions described in the oral 
solution IPM. Medication should be kept in a secured locked area at the study site 
in accordance with applicable regulatory requirements. Returned medication 
should be stored separately from medication that needs to be dispensed.   
 
To ensure adequate records, PD 0332991 capsules and oral solution will be 
accounted for as instructed by Pfizer. Unless otherwise authorized by Pfizer, at the 
end of the clinical trial all drug supplies unallocated or unused by the subjects must 
be returned to Pfizer or its designee. All containers of PD 0332991 that were sent 
to the investigator throughout the study must be returned to the sponsor or designee, 
whether they are used or unused, and whether they are empty or contain 
capsules /solution . 
  
Protocol Version:  Amendment 6; 10/24/17   Page 39 of 73 
  
8.1.7 Administration  
 
Patients should be encouraged to take their dose of PD 0332991 at approximately 
the same time each day.  Patients should be instructed to record daily  
administration of the study drugs in a patient diary.  
 
Patients must be instructed to withhold their daily dose of PD 0332991  on 
pharmacokinetic sampling days until the pre -dose pharmacokinetic sample and 
safety assessments (ie, hematology, blood chemistr y and ECGs) have been 
completed.  On days the patient is in the clinic, PD 0332991  will be taken when 
instructed by the investigator.  
 
Patients who miss a day’s dose must be instructed NO T to “make it up” the next 
day. Patients who vomit any time after tak ing a dose must be instructed NOT to 
“make it up,” and to resume treatment the next day as prescribed. Patients who 
inadvertently take 1  extra dose during a day must be instructed to skip the next 
day’s dose  
 
PD 0332991  Capsules  
Patients should be instruct ed to swallow PD 0332991 capsules whole and not to 
chew them  prior to swallowing. No capsule should be ingested if it is broken, 
cracked, or otherwise not  intact. PD 0332991 capsules will be administered once a 
day, orally, for 21 days followed by 7 days o ff treatment in 28 -day cycles.  Patients 
should take PD 0332991 with food .  
 
PD 0332991 Oral Solution  
For patients who are unable to swallow capsules, a PD 0332991  oral solution is 
available as of IRB/EC approval of Amendment 5.  
 
For patients who develop inability to swallow capsules during the study, it is 
allowed to switch to the PD 0332991  oral solution.  
 
The PD 0332991  oral solution (25 mg/mL) will be administered using an oral 
syringe at volumes corresponding to the dose pres cribed by the investigator (125 
mg dose = 5mL, 100 mg dose = 4 mL, and 75 gm dose = 3 mL). Detailed 
instructions for administration of the oral solution can be found in the DAI.  
 
PD 0332991  oral solution will be administered once a day, orally or via feed ing 
tube, for 21  days followed by 7  days off treatment in 28 -day cycles.  The route of 
administration of the oral solution (oral vs via feeding tube) will be recorded in 
patient’s dosing diary and the study  CRF.  
 
Patients can take PD 0332991 oral solution with or without food . 
  
Protocol Version:  Amendment 6; 10/24/17   Page 40 of 73 
  
8.1.8 Special Handling Instructions  
 
Females of childbearing potential should not handle or administer the study agent 
unless they are wearing gloves.  
 
8.1.9 Pregnancy  
 
The nonclinical safety profile of palbociclib has been well characterized through 
the conduct of single - and repeat -dose toxicity studies up to 39 weeks in duration, 
and safety pharmacology, genetic toxicity, reproductive and developmental 
toxicity, and phototoxicity studies.  Consistent with the pharmacologic activity of 
palboc iclib (cell cycle inhibition, CDK4/6 inhibition), the primary target organ 
findings included hematolymphopoietic (decreased cellularity of bone marrow and 
lymphoid organs) and male reproductive organ (seminiferous tubule degeneration, 
and secondary effects  on the epididymis, prostate, and seminal vesicle) effects in 
rats and dogs, and altered glucose metabolism that was accompanied by effects on 
the pancreas and secondary changes in the eye, teeth, kidney, and adipose tissue in 
rats only, and effects on bon e in rats only that were observed following single 
and/or repeat dosing at clinically relevant exposures.  Altered glucose metabolism 
(hyperglycemia/glucosuria) correlated with pancreatic islet cell vacuolation that 
was determined to reflect a loss of beta  cells with corresponding decreases in insulin 
and C -peptide.  The reversibility of the effects on glucose homeostasis, pancreas, 
eye, kidney, and bone was not established following a 12 -week non -dosing period; 
whereas partial to full reversal of effects o n the hematolymphopoietic and male 
reproductive systems, teeth, and adipose tissue were observed.  Additionally, a 
potential for QTc prolongation and hemodynamic effects were identified from 
safety pharmacology studies, and developmental toxicity was ident ified from 
embryo -fetal development studies in the rat and rabbit.  Though gastrointestinal 
effects would be anticipated from a cell cycle inhibitor and while effects were 
observed in rats and dogs following single - and repeat -dose studies up to 3  weeks 
in duration (emesis, fecal changes, and microscopic changes in stomach and 
intestines), the effects were of limited severity at clinically relevant doses.  
Gastrointestinal effects were not prominent in longer duration studies, limited to 
effects on the glan dular stomach and rodent -specific effects on the non -glandular 
stomach in rats following 27 weeks of intermittent dosing that did not reverse 
during a 12 -week non -dosing period.  Additional palbociclib -related findings 
considered non -adverse at tolerated d oses based on limited severity and/or absence 
of degenerative changes included cellular vacuolation in multiple tissues that was 
morphologically consistent with phospholipidosis; hepatic (increases in liver 
enzymes, hepatocellular hypertrophy/increased vac uolation), renal (increased 
CPN), adrenal (cortical cell hypertrophy), and respiratory (clinical signs, tracheal 
epithelial cell atrophy) effects; and prolonged coagulation times.  Reversibility 
(partial or full) was established for these additional toxici ties.  Finally, palbociclib 
was determined to be an aneugen, for which a no effect exposure was identified  
 
Protocol Version:  Amendment 6; 10/24/17   Page 41 of 73 
 8.1.10  QT Interval  
 
The patients enrolled in clinical studies should be closely monitored for potential  
cardiovascular symptoms. Appropriate monitoring sho uld include clinical 
examinations, vital signs, routine ECGs, and AEs monitoring. In case of QTc 
prolongation, concomitant conditions such as electrolyte unbalances or use of 
medications affecting the QT interval should be ruled out or corrected. In case o f 
clinically significant toxicities, PD 0332991 administration should be interrupted 
and the dose reduced as indicated in clinical protocols.  
 
In Study A5481001  using QTcF, 46 of 73  patients had a maximum increase from 
baseline of <30 msec and no patient had a maximum  on treatment value of   ≥500 
msec. Notably, one female patient who had received PD  0332991 at 75 mg QD on 
Schedule 3/1, had a maximum QTcF increase of 67 msec from  baseline to Cycle 1. 
Additionally, QTcF increases ranging from 39 to 51 msec co mpared to  baseline 
persisted throughout her ECG collection period of 5 subsequent cycles. After 7  
cycles, the dose was increased to 100 mg QD. The patient remained on treatment 
for a total  of 39 cycles with no cardiac related adverse events. QT data analys is for 
study A5481002  indicated no clinically significant mean changes with ECGs. 
Using Fridericia's correction in  the A5481002 study, all 17 subjects in the analysis 
had a maximum increase from baseline of  <30 msec and a maximum post -baseline 
value for QT c of <500 msec.  
 
8.2 Cetuximab (Erbitux)  
 
8.2.1 Cetuximab Description  
 
Cetuximab is an anti -EGFR human -to-murine chimeric antibody.  
 
8.2.2 Clinical Pharmacology  
 
The epidermal growth factor receptor (EGFR, HER1, c -ErbB -1) is a 
transmembrane glycoprotein that is a member of a subfamily of type I receptor 
tyrosine kinases including EGFR, HER2, HER3, and HER4. The EGFR is 
constitutively expressed in many normal epithelial tissues, including the skin and 
hair follicle. Expression of EGFR is also detected in many human cancers  including 
those of the head and neck, colon, and rectum.  
 
Cetuximab binds specifically to the EGFR on both normal and tumor cells, and 
competitively inhibits the binding of epidermal growth factor (EGF) and other 
ligands, such as transforming growth facto r-alpha. In vitro assays and in vivo 
animal studies have shown that binding of cetuximab to the EGFR blocks 
phosphorylation and activation of receptor -associated kinases, resulting in 
inhibition of cell growth, induction of apoptosis, and decreased matrix 
metalloproteinase and vascular endothelial growth factor production. Signal 
transduction through the EGFR results in activation of wild -type KRAS protein. 
Protocol Version:  Amendment 6; 10/24/17   Page 42 of 73 
 However, in cells with activating KRAS somatic mutations, the mutant KRAS 
protein is continuously act ive and appears independent of EGFR regulation.  
 
In vitro , cetuximab can mediate antibody -dependent cellular cytotoxicity (ADCC) 
against certain human tumor types. In vitro assays and in vivo animal studies have 
shown that cetuximab inhibits the growth and  survival of tumor cells that express 
the EGFR. No antitumor effects of cetuximab were observed in human tumor 
xenografts lacking EGFR expression. The addition of cetuximab to radiation 
therapy or irinotecan in human tumor xenograft models in mice resulted  in an 
increase in anti -tumor effects compared to radiation therapy or chemotherapy alone.  
 
8.2.3 Pharmacokinetics and Drug Metabolism  
 
Cetuximab administered as monotherapy or in combination with concomitant 
chemotherapy or radiation therapy exhibits nonlinear pharmacokinetics. The area 
under the concentration time curve (AUC) increased in a greater than dose 
proportional manner while clearance of cetuximab decreased from 0.08 to 0.02 
L/h/m2 as the dose increased from 20 to 200 mg/m2, and at doses >200 mg/m2, it 
appeared to plateau. The volume of the distribution for cetuximab appeared to be 
independent of dose and approximated the vascular space of 2 –3 L/m2. 
 
Following the recommended dose regimen (400 mg/m2 initial dose; 250 mg/m2 
weekly dose), concentrations o f cetuximab reached steady -state levels by the third 
weekly infusion with mean peak and trough concentrations across studies ranging 
from 168 to 235 and 41 to 85 μg/mL, respectively. The mean half -life of cetuximab 
was approximately 112 hours (range 63 –230 hours). The pharmacokinetics of 
cetuximab were similar in patients with HNSCC  and those with colorectal cancer. 
Based on a population pharmacokinetic analysis, female patients with colorectal 
cancer had a 25% lower intrinsic clearance of cetuximab than male patients. 
Qualitatively similar, but smaller gender differences in cetuxima b clearance were 
observed in patients with HNSCC . The gender differences in clearance do not 
necessitate any alteration of dosing because of a similar safety profile.  
 
8.2.4 Supplier  
 
Cetuximab is commercially available and is listed in the compendia as indicated for 
the therapy of HNSCC . 
 
8.2.5 Dosage Form  
 
Each single -use, ready to use 50 -mL vial contains 100 mg of cetuximab at a 
concentration of 2 mg/mL and is formulated in a preservative -free solution 
containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic 
heptahydrate, 0.42mg/mL sodium phosphate monobasic monohydrate, and Water 
for injection, USP.  
 
Protocol Version:  Amendment 6; 10/24/17   Page 43 of 73 
 8.2.6 Storage and Stability  
 
Cetuximab should be stored in a secure area accor ding to local regulations. Store 
vials under refrigeration at 2 C to 8 C (36 F to 46 F). DO NOT FREEZE. 
Increased particulate formation may occur at temperatures at or below 0C.  This 
product contains no preservatives.  Preparations of cetuximab in in fusion containers 
are chemically and physically stable for up to 12 hours at 2 C to 8 C (36 F to 46 
F) or up to 8 hours at controlled room temperature (20 C to 25 C; 68 F to 77 F).  
Discard any remaining solution in the infusion container after 8 h ours at controlled 
room temperature or after 12 hours at 2 to 8 C.  Discard any unused portion of the 
vial. 
 
8.2.7 Safety Precautions  
 
Appropriate mask, protective clothing, eye protection, gloves, and Class II vertical -
laminar -airflow safety cabinets are reco mmended during preparation and handling.  
Opened vials must be disposed of at the investigational center as chemotherapy or 
biohazardous waste provided documented procedures for destruction are in place.  
 
Cetuximab therapy should be used with caution in p atients with known 
hypersensitivity to cetuximab, murine proteins, or any component of this product.  
It is recommended that patients wear sunscreen and hats and limit sun exposure 
while receiving cetuximab as sunlight can exacerbate any skin reactions that  may 
occur.  
 
8.2.8 Premedication  
 
In an effort to prevent a hypersensitivity reaction, all patients should  be 
premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent 
antihistamine) IVPB given at least 30 minutes prior to the cetuximab.  
Premedication will also include  1Liter normal saline,  hydrocortisone 100 mg IVPB 
and albuterol inhalation (by nebulizer or inhaler) according to standard of care 
procedures.  
 
8.2.9 Preparation and Administration  
 
Cetuximab must not be administered as an IV push  or bolus. Cetuximab must be 
administered with the use of a low protein binding 0.22 -micrometer in -line filter. 
Cetuximab is supplied as a 50 -mL, single -use vial containing 100 mg of cetuximab 
at a concentration of 2 mg/mL in phosphate buffered saline. DO NOT SHAKE OR 
DILUTE.  
 
Cetuximab can be administered via infusion pump.  
 
Infusion Pump:  
 Draw up the volume of a vial using a sterile syringe attached to an appropriate 
Protocol Version:  Amendment 6; 10/24/17   Page 44 of 73 
 needle (a vented spike or other appropriate transfer device may be used).  
 Fill cetuximab into a sterile evacuated container or bag such as glass containers, 
polyolefin bags (e.g., Baxter Intravia), ethylene vinyl acetate bags (e.g., Baxter 
Clintec), DEHP plasticized PVC bags (e.g., Abbott Lifecare), or PVC bags.  
 Repeat procedure until the calc ulated volume has been put in to the container.  
Use a new needle for each vial.  
 Administer through a low protein binding 0.22 -micrometer in -line filter (placed 
as proximal to the patient as practical).  
 Affix the infusion line and prime it with cetuximab b efore starting the infusion.  
 Maximum infusion rate should not exceed 5 mL/min.  
 Use 0.9% saline solution to flush line at the end of infusion.  
 The infusion rate of cetuximab must never exceed 10 mg/minute (5 mL/min). 
The infusion time of cetuximab should no t exceed 4 hours. Patients must be 
continuously observed during the infusion for signs of anaphylaxis.  
 
8.2.10  Patient Monitoring  
 
Patients should be closely monitored for treatment -related adverse events, 
especially hypersensitivity reactions during the infusion  and for one post -infusion 
observation hour. Vital signs (blood pressure, heart rate, and temperature) will be 
monitored and recorded prior to the administration of cetuximab, 1/2 hour into the 
infusion, at the completion of the infusion, and 1 hour post -infusion for the initial 
dose. During all subsequent administrations of cetuximab, vital signs will be 
monitored and recorded prior to administration of cetuximab and at the end of the 
infusion; however, it is recommended that the patient be observed for 1 -hour post 
infusion.  
 
 
9.0 CORRELATIVE STUDIES  
 
9.1 Optional Tumor Biopsy  
 
9.1.1 Collection of Specimens  
 
Phase II patients (Arms 1 and 2 only) will be asked to consent to three  optional 
tumor biopsies, the first at pre -treatment and the second at the  end of Cycle 2 
(between Days 15 and 21 inclusive)  and the third at disease progression (from 
cetuximab and PD0332991 ). 
 
Tumor tissue biopsy site will be chosen by the PI.  Readily accessible sites for 
biopsy such as subcutaneous or dermal soft tissue masses or neck nodal mas ses will 
not likely require image guidance.  In those tumor sites that are not readily 
accessible for biopsy such as deep neck masses or visceral organ metastases, image 
guidance (ultrasound or CT) will be used.  The biopsy will consist of a minimum 
of 4 n eedle cores (14 gauge is preferred) or 2 small (each 4 x 4 x 4 mm) pieces of 
tumor.  Tissue should be delivered on saline within 30 minutes of collection.  Tissue 
Protocol Version:  Amendment 6; 10/24/17   Page 45 of 73 
 is to be stored at the Siteman Cancer Center Tissue Procurement Core Facility until 
analysis in the lab of Dr. Van Tine . The optional pre -treatment  and Cycle 2 Day 
15-21 and disease progression  tumor biopsies (core or excisional/incisional) will 
be used to perform RNAseq, p16 expression, Ki-67 by IHC, total and phospho -Rb 
by IHC, Cyclin D1 by IHC, and TUNEL assay, and to analyze other potential 
biomarkers as they emerge from the scientific understanding of PD0332991 activity 
on formalin -fixed paraffin -embedded (FFPE) tissue.  
 
9.1.2 Handling of Specimens  
 
Tissue should be sent to the Tissue Procurement Core Facility for processing and 
storage until analysis.  
 
9.2 Archival Tumor Tissue  
 
Fifteen slides are needed (minimum of 4 accepted).  
 
9.2.1 Phase I  
 
Eight additional slides will be collected for each patient.  
 
p16 by IHC will be performed on al l patients if not already available for review . 
 
Analysis of cyclin D1 expression as well as total and phospho -Rb by IHC will be 
performed on all archived specimens.  
 
9.2.2 Phase II  
 
p16 by IHC will be performed on all patients to determine eligibility  and arm 
assignment . 
 
Analysis of cyclin D1 expression as well as total and phospho -Rb by IHC will be 
performed on all archived specimens.  
 
9.3 Blood for Pharmacokinetic Analysis  
 
Blood for pharmacokinetic analysis will be drawn from all Phase I and Phase II Arm 1 
patients only.  Blood will be drawn at the following time points:  
 Cycle 1 Day 15 pre -cetuximab  
 Cycle 1 Day 15 post -cetuximab  
 Cycle 1 Day 22 pre -cetuximab  
 Cycle 1 Day 22 po st-cetuximab  
 Cycle 2 Day 15 pre -PD 0332991  
 Cycle 2 Day 15 immediately post -PD 0332991  
 Cycle 2 Day 15 pre -cetuximab  
 Cycle 2 Day 15 immediately post -cetuximab  
Protocol Version:  Amendment 6; 10/24/17   Page 46 of 73 
  Cycle 2 Day 15 1 hour post -PD 0332991  
 Cycle 2 Day 15 2 hours post -PD 0332991  
 Cycle 2 Day 15 4 hours  post-PD 0332991  
 Cycle 2 Day 15 8 hours post -PD 0332991  
 Cycle 2 Day 22 pre -cetuximab  
 Cycle 2 Day 22 post -cetuximab  
 
9.3.1 PD 0332991 PK Collection and Processing  
 
For each time point, collect 3 mL of venous blood into K 2EDTA tubes.  Upon 
collection of the blood PK samples, keep them on wet ice at all times prior to 
processing the plasma.  Samples will be centrifuged at approximately 1700 x g for 
about 10 minutes at 4°C.  The plasma will be stored in an appropriately labeled 
amber screw -capped polypropylene tube a t approximately -70°C  within 1 hour of 
collection.  Specimens will be batch shipped to a lab designated by Pfizer at a later 
date.  
 
9.3.2 Cetuximab PK Collection and Processing  
 
For each time point, collect 3 mL of venous blood into a red top glass tube 
containing no additive. Upon collection of the blood PK samples, keep them on wet 
ice to allow blood to clot prior to processing to serum.  Samples will be centrifuged 
at approximately 1700 x g for about 10 minutes in a refrigerated centrifuge at 4°C 
to ha rvest serum.  Rapidly transfer a minimum of 1 mL serum into the pre -labeled 
2 mL clear polypropylene storage cryovial. The samples will be stored in a freezer 
at approximately -20°C within 1 hour of collection.  Ship frozen samples to CRO 
on dry ice.  
 
9.4 Qual ity of Life  
 
The EORTC QLQ -C30 (Appendix E) and FACT H&N (Appendix F) will be given at 
baseline  and on Day 1 of Cycles 2, 3, 4, and 6  for patients in Phase II ( all 3 arms) only . 
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 47 of 73 
  
10.0 STUDY CALENDAR  
 
Screening  evaluations are to be conducted within 28 days p rior to start of protocol therapy.   
 
Screening  Weekly 
during 
Cycle 1  Prior to Day 1 of each 
cycle  (every 4 weeks 
Cycle 2 and beyond)p EOT  F/Uj 
Physical exam  X X X X  
Vitals signs  X X  Xa X  
Performance status  X X X X  
Adverse event assessment      X ---------------------------------------------------------- --- Xk 
CBC  X X Xb X  
Chemistry panel, LFTsf X X X X  
Pregnancy test  X   X  
EKG  X Xc Xc   
CT neck and chest  Xd  Xd   
Archival tissue  Xm     
Optional t umor biopsy  Xe  Xe X  
QOLs (Phase II only)  X  Xn   
Blood for PKso  Refer to Section 9.3    
PD0332991g  X ------------------------------------  Xg   
Cetuximabh  X --------------------------------------  Xh   
aVital signs should be taken weekly , even if treatment is held for toxicity . This can  occur at chemotherapy visits when 
not having physical exams.  
bCBC to be performed weekly throughout all cycles , even if treatment is held for toxicity   
cEKG: Day 22 of each cycle  
dTumor assessments with CT of neck and chest will be performed at screening and at subsequent  8 week  interval s 
(every 2 cycles) . 
eTumor biopsies will be encouraged at baseline and at Cycle 2 Day 15 -21 and at disease progression  in patients in for 
Phase II patients (Arms 1 and 2 only). Cyclin D1, p16 by IHC, Ki -67, RNAseq, total and phospho -Rb and TUNEL 
assays will be performed on all three  tissue sets.  
fChemistry includes Ca, Mg, K, Na, glucose, albumin, urea, creatinine; LFTs include  ALT , AST, alkaline phosphatase, 
total bilirubin ; please refer to Section 7.8 for special LFT AE reporting guidance.  
gPD0332991  will be taken orally on Days 1 -21 of a 28 day cycle.  
hCetuximab will be administered weekly  
jFollow -up will consist of checks every 2 months  (+/- 2 weeks)  for recurrence and survival for 5 years ; this may be 
done over the phone or as a review of the medical record.  
kAdverse events should be collected for 30 days after the last dose of study treatment.  
mp16, cyclin D1 , and total and phospho -Rb will be assessed from FFPE tissue (15 slides, minimum of 4 accepted) on 
all patients (p16 to be done at screening ; other testing to be performed at a later date)  
nAdminister QOLs at C2D1, C3D1, C4D1, and C6D1.  
oPhase I and Phase II Arm 1 only  
p+/- 2 day window for visits  
 
 
11.0 DATA SUBMISSION SCHEDULE  
 
Case report forms with appropriate source documentation will be completed according to the 
schedule listed in this section.  
Protocol Version:  Amendment 6; 10/24/17   Page 48 of 73 
  
Electronic data management systems will be used in this trial in collaboration with the Institute for  
Informatics at Washington Universi ty.   
 
REDCap  is a web -based clinical studies data management system that will be used for capture of 
clinical data from this trial.   An electronic study calendar will drive the study’s data collection 
workflow.   Each participating center has access only to data from its own participants  by creation 
of Data Access Groups .  Washington University, as the data coordinating center, has access to data 
from all sites.  
 
Case Report Form  Submission Schedule  
Original Consent Form  Prior to registration  
Demographics Form  
On Study Form  
On Study Prior Therapy Form  
Treatment Assignment Form  Prior to starting treatment  
Treatment Form  
EKG Form  Every cycle  
Adverse Event  Form  Continuous  
Tumor Biopsy  Form  
PKs Form  Baseline and end of Cycle 2  
QOLs Form  Baselin e and at C2D1, C3D1, C4D1, and C6D1  
Treatment Summary Form  Completion of treatment  
Follow Up Form  Every 2 months for 5 years  
Tumor Measurement Form  Baseline, end of every even numbered cycles, 
and end of treatment  
MedWatch Form  See Section 7.0 for reporting requirements  
 
Any queries generated by Washington University must be responded to within 28 days of receipt 
by the participating site.  The Washington University research team will conduct a regular review 
of data status at all secondary sites, with appropriate corrective action to be requested as needed.  
 
 
12.0 MEASUREMENT OF EFFECT  
 
12.1 Antitumor Effect – Solid Tumors  
 
For the purposes of this study, patients should be re -evaluated for response every 8 weeks.  
In addition to a baseline scan, confirmatory scans should also be obtained not less than 4 
weeks following initial documentation of objective response.  
 
Response and progression will be evaluated in this study using the new international 
criteria proposed by the revised Response Evaluati on Criteria in Solid Tumors (RECIST) 
guideline (version 1.1) [Eur J Ca 45:228 -247, 2009].  Changes in the largest diameter 
(unidimensional measurement) of the tumor lesions and the shortest diameter in the case 
of malignant lymph nodes are used in the RECI ST criteria.  
Protocol Version:  Amendment 6; 10/24/17   Page 49 of 73 
  
12.2 Disease Parameters  
 
Measurable disease :  Measurable lesions are defined as those that can be accurately 
measured in at least one dimension (longest diameter to be recorded) as >20 mm by chest 
x-ray, as >10 mm with CT scan, or >10 mm with calipers by clinical exam.  All tumor 
measurements must be recorded in millimeters (or decimal fractions of centimeters).  
 
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a 
lymph node must be >15 mm in short axis when asses sed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, only 
the short axis will be measured and followed.  
 
Non-measurable disease:   All other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), 
are considered non -measurable disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast dise ase, 
and abdominal masses (not followed by CT or MRI), are considered as non -measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should 
not be considered as malignant lesions (neither measurable nor non -measu rable) since 
they are, by definition, simple cysts.  
 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non -
cystic lesions are present i n the same patient, these are preferred for selection as target 
lesions.  
 
Target lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target lesions 
and recorded and measured at baseline.  Target lesions should be selected on the basis of 
their size (lesions with the longest diameter), be representative of all involved organs, but 
in addition should be those that lend themselves to reproducible repeated  measurements.  
It may be the case that, on occasion, the largest lesion does not lend itself to reproducible 
measurement in which circumstance the next largest lesion which can be measured 
reproducibly should be selected.  A sum of the diameters (longest for non -nodal lesions, 
short axis for nodal lesions) for all target lesions will be calculated and reported as the 
baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short 
axis is added into the sum.  The baseline sum diam eters will be used as reference to further 
characterize any objective tumor regression in the measurable dimension of the disease.  
 
Non-target lesions :  All other lesions (or sites of disease) including any measurable lesions 
over and above the 5 target le sions should be identified as non -target lesions and should 
also be recorded at baseline.  Measurements of these lesions are not required, but the 
presence, absence, or in rare cases unequivocal progression of each should be noted 
throughout follow -up.  
Protocol Version:  Amendment 6; 10/24/17   Page 50 of 73 
  
12.3 Methods for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  
All baseline evaluations should be performed as closely as possible to the beginning of 
treatment and never more than 4 weeks before the beginning of the treatment.  
 
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow -up. Imaging -based 
evaluation is preferred to evaluation by  clinical examination unless the lesion(s) being 
followed cannot be imaged but are assessable by clinical exam.  
 
Clinical lesions:   Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and 10 mm diameter as assessed 
using calipers (e.g., skin nodules).  In the case of skin lesions, documentation by color 
photography, including a ruler to estimate the size of the lesion, is recommended.  
 
Chest x -ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI:   This guideline has defined measurability of lesions on CT 
scan based on the as sumption that CT slice thickness is 5 mm or less.  If CT scans have 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which 
greatly impact image quality, lesion conspicuity, and measurement.  Furthermore, the 
availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical 
specifications of the scanning sequences used should be optimized for the evaluation of the 
type and site of disease.  Furthermore, as with CT, the modality used a t follow -up should 
be the same as was used at baseline and the lesions should be measured/assessed on the 
same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific 
MRI pulse sequence parameters for all scanners, body parts , and diseases.  Ideally, the 
same type of scanner should be used and the image acquisition protocol should be followed 
as closely as possible to prior scans.  Body scans should be performed with breath -hold 
scanning techniques, if possible.  
 
PET -CT:  At present, the low dose or attenuation correction CT portion of a combined 
PET-CT is not always of optimal diagnostic CT quality for use with RECIST 
measurements.  However, if the site can document that the CT performed as part of a PET -
CT is of identical dia gnostic quality to a diagnostic CT (with IV and oral contrast), then 
the CT portion of the PET -CT can be used for RECIST measurements and can be used 
interchangeably with conventional CT in accurately measuring cancer lesions over time.  
Note, however, tha t the PET portion of the CT introduces additional data which may bias 
an investigator if it is not routinely or serially performed.   
Protocol Version:  Amendment 6; 10/24/17   Page 51 of 73 
  
Ultrasound:   Ultrasound is not useful in assessment of lesion size and should not be used 
as a method of measurement.  Ul trasound examinations cannot be reproduced in their 
entirety for independent review at a later date and, because they are operator dependent, it 
cannot be guaranteed that the same technique and measurements will be taken from one 
assessment to the next.  I f new lesions are identified by ultrasound in the course of the 
study, confirmation by CT or MRI is advised.  If there is concern about radiation exposure 
at CT, MRI may be used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy:   The utilization  of these techniques for objective tumor 
evaluation is not advised.  However, such techniques may be useful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials where 
recurrence following complete response (CR) or surgical resection is an endpoint.  
 
Tumor markers:   Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered 
in complete clinical response.  Sp ecific guidelines for both CA -125 response (in recurrent 
ovarian cancer) and PSA response (in recurrent prostate cancer) have been published [JNCI 
96:487 -488, 2004; J Clin Oncol 17, 3461 -3467, 1999; J Clin Oncol 26:1148 -1159, 2008].  
In addition, the Gynec ologic Cancer Intergroup has developed CA -125 progression criteria 
which are to be integrated with objective tumor assessment for use in first -line trials in 
ovarian cancer [JNCI 92:1534 -1535, 2000].  
 
Cytology, Histology:   These techniques can be used to d ifferentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).  
 
The cytological confirmation of the neoplastic origin o f any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or stable 
disease is mandatory to differentiate between response or stable disease (an effusion may 
be a side effect of the treatment) and progr essive disease.  
 
FDG -PET:   While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New le sions on the basis 
of FDG -PET imaging can be identified according to the following algorithm:  
 
 Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion.  
 No FDG -PET at baseline and a positive FDG -PET at follow -up:  If the positive 
FDG -PET at follow -up corresponds to a new site of disease confirmed by CT, this 
is PD.  If the positive FDG -PET at follow -up is not confirmed as a new site of 
disease on CT, addit ional follow -up CT scans are needed to determine if there is 
truly progression occurring at that site (if so, the date of PD will be the date of the 
initial abnormal FDG -PET scan).  If the positive FDG -PET at follow -up 
corresponds to a pre -existing site of  disease on CT that is not progressing on the 
Protocol Version:  Amendment 6; 10/24/17   Page 52 of 73 
 basis of the anatomic images, this is not PD.  
 FDG -PET may be used to upgrade a response to a CR in a manner similar to a 
biopsy in cases where a residual radiographic abnormality is thought to represent 
fibrosi s or scarring.  The use of FDG -PET in this circumstance should be 
prospectively described in the protocol and supported by disease -specific medical 
literature for the indication.  However, it must be acknowledged that both 
approaches may lead to false posi tive CR due to limitations of FDG -PET and 
biopsy resolution/sensitivity.  
  
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image.  
 
12.4 Response Criteria  
 
12.4.1  Evaluation of Target Lesions  
 
Complete Response (CR):   Disappearance of all target lesions.  Any pathological 
lymph nodes (whether target or non -target) must have reduction in short axis to <10 
mm. 
 
Partial Response (PR):   At least a 30% decrease  in the sum of the diameters of 
target lesions, taking as reference the baseline sum diameters.  
 
Progressive Disease (PD):   At least a 20% increase in the sum of the diameters of 
target lesions, taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on study).  In addition to the relative increase of 
20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  
the appearance of one or more new lesions is also considered progressions).  
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study.  
 
12.4.2  Evaluation of Non -Target Lesions  
 
Complete Response (CR):   Disappearance of all non-target lesions and 
normalization of tumor marker level.  All lymph nodes must be non -pathological 
in size (<10 mm short axis).  
 
Note:  If tumor markers are initially above the upper normal limit, they must 
normalize for a patient to be considered in co mplete clinical response.  
 
Non-CR/Non -PD:  Persistence of one or more non -target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.  
 
Progressive Disease (PD):   Appearance of one or more new lesions and/or 
Protocol Version:  Amendment 6; 10/24/17   Page 53 of 73 
 unequivocal progression of  existing non -target lesions.  Unequivocal progression 
should not normally trump target lesion status.  It must be representative of overall 
disease status change, not a single lesion increase.     
 
Although a clear progression of “non -target” lesions only  is exceptional, the 
opinion of the treating physician should prevail in such circumstances, and the 
progression status should be confirmed at a later time by the review panel (or 
Principal Investigator).  
 
12.4.3  Evaluation of Best Overall Response  
 
The best over all response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started).  The 
patient's best response assig nment will depend on the achievement of both 
measurement and confirmation criteria.  
    
For Patients with Measurable Disease (i.e., Target Disease)  
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response 
when Confirmation is 
Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR/Non -
PD No PR 
>4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -
PD/not 
evaluated  No PR 
SD Non-CR/Non -
PD/not 
evaluated  No SD Documented at least once 
>4 wks. from baseline**  
PD Any Yes or  
No PD 
no prior SD, PR or CR  Any PD***  Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new 
lesion.  
** Only for non -randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non -target lesions 
may be accepted as disease progression.  
Note:  Patients with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of disease progression at tha t time should be 
reported as “symptomatic deterioration.”  Every effort should be made to document 
the objective progression even after discontinuation of treatment.  
 
Protocol Version:  Amendment 6; 10/24/17   Page 54 of 73 
                                       For Patients with Non -Measurable Disease (i.e., Non-Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non-target disease 
since SD is increasingly used as an endpoint for assessment of efficacy in 
some trials so to assign this category when no lesions can be measured is not 
advised  
  
12.4.4  Duration of Response  
 
Duration of overall response:   The duration of overall response is measured from 
the time measurement criteria are met for CR or PR (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for progressive d isease the smallest measurements recorded 
since the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria are first 
met for CR until the first date that progressive disease is objectively documented.   
 
Duration of disease control (CR, PR, stable disease) :  Disease control  is 
measured from the start of the treatment until the criteria for progression are met, 
taking as reference the smallest measurements recorded since the treatment started, 
including the baseline mea surements.  
 
12.4.5  Efficacy  
 
Efficacy will be measured by the overall response rate (CR+PR) defined by 
RECIST criteria and by time to progression.  
 
12.4.6  Progression -Free Survival  
 
Progression -free survival i s defined as the duration of time from start of treatment 
to time of progression or death, whichever occurs first.  
 
12.4.7  Overall Survival  
 
Overall survival is measured from time of diagnosis to time of death.  
 
12.4.8  Response Review  
 
All responses will be reviewed by an expert independent of the study at the study’s 
completion.  Simultaneous review of the patients’ files and radiological images is 
Protocol Version:  Amendment 6; 10/24/17   Page 55 of 73 
 the best approach.  
 
 
13.0 DATA AND SAFETY MONITORING  
 
In compliance with the Washington University Institutional Data and Safety Monitoring Plan, an 
independent Data and Safety Monitoring Committee (DSM C) will be specifically convened for 
this trial  to review toxicity data at least every 6 months following th e activation of the first 
secondary site.  A DSMC will consist of no fewer than 3 members including 2 clinical investigators 
and a biostatistician.   Like investigators, DSMC members are subject to the Washington University 
School of Medicine  policies regar ding standards of conduct. Individuals invited to serve on the 
DSMC will disclose any potential conflicts of interest to the trial principal investigator and/or 
appropriate university officials, in accordance with institution policies. Potential conflicts that 
develop during a trial or a member’s tenure on a DSMC must also be disclosed.  
 
The DSM report will be prepared by the study statistician with assistance from the study team , 
will be reviewed by the DSMC,  and will be submitted to the Quality Assurance  and Safety 
Monitoring Committee (QASMC).  
 
Note that d uring the phase I dose escalation, the Principal Investigator will review all patient data 
at least monthly (or before each dose -escalation if occurring sooner than monthly), and provide a 
semi -annual r eport to the QASMC.   The report provided to QASMC  will include:  
 
 HRPO protocol number, protocol title, Principal Investigator name, data coordinator name, 
regulatory coordinator name, and statistician  
 Date of initial HRPO approval, date of most recent cons ent HRPO approval/revision, date 
of HRPO expiration, date of most recent QA audit, study status, and phase of study  
 History of study including summary of substantive amendments; summary of accrual 
suspensions including start/stop dates and reason; and summ ary of protocol exceptions, 
error, or breach of confidentiality including start/stop dates and reason  
 Study -wide target accrual and study -wide actual accrual  including numbers from 
participating sites  
 Protocol activation date  at each participating site  
 Average rate of accrual observed in year 1, year 2, and subsequent years  at each 
participating site  
 Expected accrual end date , accrual by cohort , and accrual by site  
 Objectives of protocol with supporting data and list the number of participants who have 
met each objective  
 Measures of efficacy  
 Early stopping rules with supporting data a nd list the number of participa nts who have met 
the early stopping rules  
 Summary of toxicities at all participating sites separated by cohorts with the number of 
dose-limiting toxicities indicated  
 Abstract submissions/publications  
 Summary of any recent literature that may affect the safety or ethics of the study  
 
Protocol Version:  Amendment 6; 10/24/17   Page 56 of 73 
 Further DSMC responsibilities are described in the DSMC charter.  
 
Until such a time as the first secondary site activates this protocol, a semi -annual DSM report to 
be prepared by the study team will be submitted to the QASMC beginning 6 months after study 
activation at Washington University.  
 
The study principal investigator and coordinator will monitor for serious  toxicities on an ongoing 
basis. Once the principal investigator or coordinator becomes aware of an adverse event, the AE 
will be reported to the HRPO and QASMC according to institutional guidelines  (please refer to 
Section 7.0) . 
 
Refer to the Washington U niversity Quality Assurance and Data Safety Monitoring Committee 
Policies and Procedures for full details on the responsibilities of the DSMC at 
https://siteman.wustl.edu/wp -content/uploads/2015/10/QASMC -Policies -and-Procedures -
03.31.2015.pdf   
 
14.0 AUDITING  
 
As coordinating center of this trial, Washington University (via the Quality Assurance and Safety 
Monitoring Committee (QASMC) will monitor eac h participating site to ensure that all protocol 
requirements are being met; that applicable federal regulations are being followed; and that best 
practices for patient safety and data collection are being followed per protocol.   Participating  sites 
will b e asked to send copies of all audit materials, including source documentation.  The audit 
notification will be sent to the Washington University Research Patient Coordinator, who will 
obtain the audit materials from the participating institution.  
 
Notifica tion of an upcoming audit will be sent to the research team one month ahead of the audit. 
Once accrual numbers are confirmed, and approximately 30 days prior to the audit, a list of the 
cases selected for review (up to 10 for each site) will be sent to the  research team. However, if 
during the audit the need arises to review cases not initially selected, the research team will be 
asked to provide the additional charts within two working days.  
 
Items to be evaluated include:  
 Subject screening and enrollment  
 Reporting of adverse events  
 Maintenance of HIPAA compliance  
 Completeness of regulatory documentation  
 Completeness of participant documentation  
 Acquisition of informed consent  
 IRB documentation  
 Issues of protocol adherence  
 
Additional details regarding the auditing policies and procedures can be found at 
https://siteman.wustl.edu/wp -content/uploads/2015/QASMC -Policies -and-Procedures -
03.31.2015.pdf   
 
Protocol Version:  Amendment 6; 10/24/17   Page 57 of 73 
  
15.0 STATISTICAL CONSIDERATIONS  
 
This trial consists of an open -label phase I study, where the MTD and DLT of the combination of 
PD 0332991 will be determined, followed by a phase II study where patients with incurable HPV -
unrelated SCCHN will be treated with PD 0332991 and cetuximab.  Th e phase I portion of the 
study will adopt a 3 + 3 design and at most 12 patients will be needed in this group.  
 
Dose escalations and de -escalations will proceed as follows after the occurrence of dose -limiting 
toxicity (DLT):  
 
Cohort  # DLTs  Escalation Dec ision Rule  
1 0 Escalate to dose 2.  
 1 Enter 3 additional patients at dose 1.  
 2 De-escalate to dose -1. 
2 0 Conclude that the MTD has not yet been reached.  
 1 Enter 3 additional patients at dose 2 if 0 in cohorts 1 
and 2. Identify dose 2 as the MTD if  1 in cohorts 1 
and 2.  
 2 Conclude that dose 1 is the MTD.  
 
For the phase II Arm 1 portion, based upon currently available data for cetuximab alone in platin -
resistant  incurable SCCHN37, an overall tumor response rate (CR + PR) of 13% or lower would 
be unacceptable and an overall tumor response rate of 26% or higher of clinical interest.  A total 
of 30 eligible and evaluable patients will be accrued to the phase II portion of the study, and if 4 
or more patients’ tumors respond, the therapy will be accept ed for further investigation.  The 
design is based on Thall P and Sung H -G38. 
 
Assumes 13% response with standard treatment, response rate increase of 13% (26% response rate 
with experimental treatment), expected (grade 3 or 4) toxicity rate of 46% with standard, 0% 
allowable increase with experimental treatment . 
 
Stop for poor response if:  Stop for excess (grade 3 or 4) toxicity if:  
# Patients is:  # Responses is ≤:  # cases of toxicity is 
≥: In 1st # patients  
3 0   
4 0 4 4 
5 0 5 5 
6 0 5 6 
7 0 6 7 
8 0 7 8 
9 0 7 9 
10 0 8 10 
11 0 8 11 
12 1 9 12 
13 1 10 13 
Protocol Version:  Amendment 6; 10/24/17   Page 58 of 73 
 14 1 10 14 
15 1 11 15 
16 1 11 16 
17 1 12 17 
18 2 13 18 
19 2 13 19 
20 2 14 20 
21 2 14 21 
22 2 15 22 
23 2 15 23 
24 3 16 24 
25 3 17 25 
26 3 17 26 
27 3 18 27 
28 3 18 28 
29 3 19 29 
30 3 19 30 
 
 
For the phase II arm 2 portion, the tumor response rate to any agent in patients with cetuximab -
resistant  incurable SCCHN is unknown but it is expected to be < 13%.  An overall tumor response 0123456789101112131415161718192021222324252627282930
0123456789101112131415161718192021222324252627282930The trial will be suspended for review if the number of responses is 
on or below the lower (blue) line or the number of cases of (grade 3 or 
4) toxicity is on or above the upper (red) line:
# Responses # Cases of ToxicitySTOP FOR EXCESS TOXICITY
CONTINUE
STOP FOR POOR RESPONSE
Protocol Version:  Amendment 6; 10/24/17   Page 59 of 73 
 rate (CR+PR) of 13% or lower would be unacceptable and an overall tumor response rate of 26% 
or higher would be of clinical interest.  A total of 30 eligible and evaluable patients will be accrued 
to the phase II arm 2 portion of the study, and if 4 or more patients’ tumors respond, the therapy 
will be acc epted for further investigation.  The design is based on Thall P and Sung H -G38.  The 
table and figure above also apply to phase II Arm 2.  
 
For phase II Arm 3 portion, an overall tumor response rate (CR + PR) of 5% or lower would be 
unacceptable and an ove rall tumor response rate of 20% or higher of clinical interest. A total of 24 
eligible and evaluable patients will be accrued to this arm. One or more tumor responses in the first 18 
patients are required to continue enrollment. Two or more tumor responses  in the first 24 patients are 
required to accept the alternative hypothesis. The design has probability = .74 of early stopping after 
the first cohort of 18 patients if the true response rate is 5% or less. The cumulative probability of 
completing the stud y (enrolling 24 patients) is 0.70 if the true response rate is 20% or greater. The 
design is based on Thall P and Sung H -G38. 
 
Number 
of patients  Cumulative probability 
of early stopping if 
response rate = 5%  
(null hypothesis)  Cumulative probability of 
early stopping if response 
rate = 20%  
(minimum alternative 
hypothesis)  Cumulative probability of 
continuing to end of study 
if response rate = 20%  
(minimum alternative 
hypothesis)  
1 0 0 0 
18 0.7436  0.2858  .7142  
24 0.8335  0.2953  .7047  
 
15.1 Correlative Studies  
 
Standard statistical methods will be used to describe cyclin D1 and p16 results by IHC, 
which will then be correlated to overall tumor response and TTP in Phase II patients.  
Similarly, RNAseq, Ki-67, total and phospho -Rb, and  TUNEL assay performed on paired 
pre-Cycle 1  and post -Cycle 2 FFPE tumor tissue will be described and compared using 
standard statistical methods.  
 
 
16.0 MULTICENTER REGULATORY REQUIREMENTS  
 
Washington University requires that each participating site sends its informed consent document 
to be reviewed and approved by the Washington University Regulatory Coordinator (or designee) 
prior to IRB/IEC submission.    
 
Site activation is defined as when the secondary site has received official written documentation 
from the coordinating center that the site has been approved to begin enrollment.  At a minimum, 
each participating institution must have the following documents on file at Washington University 
prior to study activation : 
 Documentation of IRB approval of the st udy in the form of a letter or other official 
document from the participating institution’s IRB.  This documentation must show 
which version of the protocol was approved by the IRB.  
Protocol Version:  Amendment 6; 10/24/17   Page 60 of 73 
  Documentation of IRB approval of an informed consent form. The consent mus t 
include a statement that data will be shared with Washington University, including the 
Quality Assurance and Safety Monitoring Committee (QASMC), the DSMC (if 
applicable), and the Washington University study team.  
 Documentation of FWA, signed FDA Form 15 72 (if applicable) , and the CVs of all 
participating investigators.  
 Protocol signature page signed and dated by the investigator at each participating site.  
 
The coordinating center Principal Investigator  (or designee)  is responsible for disseminating to the 
participating sites all study updates, amendments, reportable adverse events, etc.  Protocol/consent 
modifications and IB updates will be forwarded electronically to the secondary sites within 4 
weeks of obtaining W ashington University IRB approval.  Activated s econdary sites are  expected 
to submit protocol/consent/IB modifications to their local IRBs within 4 weeks of receipt , unless 
otherwise noted .  Upon the secondary sites obtaining local IRB approval, documentat ion of such 
shall be sent to the Washington University study team within 2 weeks of receipt of approval.  
 
Documentation of participating sites’ IRB approval of annual continuing reviews, protocol 
amendments or revisions, all SAE reports, and all protocol v iolations/deviations/exceptions must 
be kept on file at Washington University.  
 
The investigator or a designee from each institution must participate in a regular conference call 
to update and inform regarding the progress of the trial.  
  
Protocol Version:  Amendment 6; 10/24/17   Page 61 of 73 
  
17.0 REFERENCES  
 
1 Ang K, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl 
J Med.  363, 24–35 (2010).  
2 Chung C, et al . Molecular classification of head and neck squamous cell carcinomas using 
patterns of gene expression. Cancer Cell.  5, 489–500 (2004).  
3 Chung C, et al . Gene expression profiles identify epithelial -to-mesenchymal transition and 
activation of nuclear factor -kB signaling as characteristic of a high risk squamous cell carcinoma. 
Cancer Res.  66, 8210 –8218 (2006).  
4 Bonner J, et al. Radiotherapy plus cetuximab for squamous -cell carcinoma of the head and neck. 
N Engl J Med. 354, 567 –578 (2006).  
5 Vermorken J, et al. Platinum -Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N 
Engl J Med . 359 1116 -1127 (2008).  
6 Smeets S,  et al. Genome -wide DNA copy number alterations in head and neck squamous cell 
carcinomas with or without oncogene -expressing human papillomavirus. Oncogene 25, 2558 –
2564 (2006).  
7Bova R, et al. Cyclin D1 and p16INK4A expression predict reduced s urvival in carcinoma of the 
anterior tongue. Clin Cancer Res . 5, 2810 -2819 (1999).  
8Akervall J, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck 
and the prognostic value of chromosomal abnormalities and cyclin D1 overexpres sion. Cancer . 
79, 380 -389 (1997).  
9Okami K, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck 
squamous cell carcinoma. Oncogene . 18, 3541 -3545 (1999).  
10Liu S, et al. Image cytometry of cyclin D1: a prognostic marker for he ad and neck squamous cell 
carcinomas. Cancer Epidemiol Biomark Prev . 10, 455 -459 (2001).  
11Kyomoto R, et al . Cyclin -D1-gene amplification is a more potent prognostic factor than its 
protein over -expression in human head -and-neck squamous -cell carcinoma. Int J Cance r. 74, 576 -
581 (1997).  
12Muller D, et al . Amplification of 11q13 DNA markers in head and neck squamous cell 
carcinomas: correlation with clinical outcome. Eur J Cancer . 33, 2203 -2010 (1997).  
13Mineta H, et al. Cyclin D1 overexpression correlates  with poor prognosis in patients with tongue 
squamous cell carcinoma. Oral Oncol . 36, 194 -198 (2000).  
14Michalides R, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell 
carcinoma  
of the head and neck. Arch Otolaryngol Head Neck Surg . 123, 497 -502 (1997).  
15Jares P, et al . PRAD -1/cyclin D1 gene amplification correlates with messenger RNA 
overexpression and tumor progression in human laryngeal carcinomas. Cancer Res . 54, 4813 -4817 
(1994).  
16 Scantlebury J, et al. Cyclin D1 —a progn ostic marker in oropharyngeal squamous cell carcinoma 
that is tightly associated with high -risk human papillomavirus status. Human Path ol. 2013 Aug; 
44(8): 1672 -80.  
17 Reed A, et al. High frequency of p16 (CDKN2/MTS -1/INK4A) inactivation in head and neck 
squamous cell carcinoma. Cancer Res. 56, 3630 –3633 (1996).  
18 Smeets S,  et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and 
pRb pathways. Int J Cance r. 128, 1596 -1605 (2011) . 
Protocol Version:  Amendment 6; 10/24/17   Page 62 of 73 
 19 Lin S, et al. Nuclear localization of EGF receptor and its potential new role as a transcription 
factor. Nature Cell Biol. 3, 802 –808 (2001).  
20 Kalish L, et al. Deregulated Cyclin D1 Expression Is Associated with Decreased Eff icacy of the 
Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and 
Neck Squamous Cell Carcinoma Cell Lines. Clin Cancer Res . 10, 7764 -7774 (2004).  
21 Kobayashi S, et al . Transcriptional Profiling Identifies Cyclin D1 as  a Critical Downstream 
Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Res . 66, 11389 -11398 
(2006).  
22 Zhang P, et al . Identification of genes associated with cisplatin resistance in human oral 
squamous cell carcinoma cell line. BMC Cancer . 6, 224 (2006).  
23 Zhou X, et al. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous 
cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer . 124, 
483-489 (2009).  
24 Feng Z, et al. CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with 
Locally Advanced Head and Neck Squamous Cell Carcinoma. PLoS ONE . 6, e26399 (2011).  
25 Hirama T. and H. Phillip Koeffler. Role of the Cyclin -Dependent Kinase Inhibitors in the 
Development of Cancer. Blood.  86, 841 -854 (1995).  
26 Fry D. et al. Specific Inhibition of cyclin -dependent kinase 4/6 by PD 0332991 and associated 
antitumor activity in human tumor xenografts. Mol cancer Ther . 3, 1427 -1437 (2004).  
27 Finn R, et al . PD 03329 91, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits 
proliferation of luminal estrogen receptor -positive human breast cancer cell lines in vitro. Breast 
Cancer Res.  11, 1-13 (2009)  
28 Baughn L, et al. A Novel Orally Active Small Molecule  Potently Induces G1 Arrest in Primary 
Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin -Dependent Kinase 
4/6. Cancer Res. 66, 7661 -7668 (2006).  
29 Flaherty K, et al . Phase I, Does -Escalation Trial of the Oral Cyclin -Dependent Kinase 4/6 
Inhibitor PD 0332991, Administered Using a 21 -Day Schedule in Patients with Advanced Cancer. 
Clin Cancer Res . 18, 568 -576 (2012).  
30 Schwartz G, et al . Phase I study of PD 0332991, a cyclin -dependent kinase inhibitor, 
administered in 3 -week cycles (Schedule 2/1). Brit J Cancer . 104, 1862 -1868 (2011).  
31 ASCO Accepted Poster Presentation #3060. Phase 1 study of PD 0332991, a cyclin -D kinase 
(CDK) 4/6 inhibitor in combination with letroz ole for first -line treatment of patients with ER -
positive, HER2 -negative breast cancer. Monday, June 7, 2010: 8:00am -12:00pm. D. Slamon – 
Presenter. 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). June 4 -8, 
2010.     
32 Finn R, et al. Preliminary results of a randomized phase 2 study of PD 0332991, a cyclin -
dependent kinase 4/6 inhibitor, in combination with letrozole for first -line treatments of patients 
with postmenopausal, ER -positive, HER2 -negative advanced breast cancer. Presen ted at: SABCS  
33 Finn R, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin -dependent kinase 
(CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first -line treatment of 
ER+/HER2 - advanced breast cancer (BC). Cancer R es. 72, 91s (2012).  
34 Leonard J, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients 
with mantle cell lymphoma. Blood . 119, 4597 -4607 (2012).  
35 Pickering C, et al . Integrative genomic characterization of oral squamous cell ca rcinoma 
identifies frequent somatic drivers. Cancer Disc . OnlineFirst: April 25, 2013.  
Protocol Version:  Amendment 6; 10/24/17   Page 63 of 73 
 36 Morris L, et al. The molecular landscape of recurrent and metastatic head and neck cancers: 
Insights from a precision oncology sequencing platform. JAMA Oncol . 3(2), 244-255 (2017).  
37 Vermorken, J. B. et al. Open -label, Uncontrolled, Multicenter Phase II Study to Evaluate the 
Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or 
Metastatic Squamous Cell Carcinoma of the Head and Neck W ho Failed to Respond to Platinum -
Based Therapy. J Clin Oncol . 25, 2171 -2177 (2007).  
38 Thall P and Sung H -G. Some extensions and applications of a Bayesian strategy for 
monitoring multiple outcomes in clinical trials, Statistics in Medicine  17, 1563 -1580  (1998).  
 
 
We would like to thank the Alvin J. Siteman Cancer Center at Washington University School of 
Medicine and Barnes -Jewish Hospital in St. Louis, Missouri, for the use of the Clinical Trials Core 
which provided protocol development  service. The Sitem an Cancer Center is supported in part by 
an NCI Cancer Center Support Grant #P30 CA91842.  
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 64 of 73 
 APPENDIX A : ECOG Performance Status Scale  
 
 
Grade  
  
Description  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable  of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% 
of waking hours.  
3  
In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
 
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5  
Dead.  
 
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 65 of 73 
 APPENDIX B: Medication Diary  
 
Today’s Date:      Agent:  PD 0332991  Cycle:     Study ID#:     
 
Formulation: ___ Liquid   ___ Capsules   Route (if liquid): ___ By mouth   ___ Feeding tube  
 
INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each month.  Take _____mg of PD 0332991  at approximately the same time each day  
with food  (if capsules) or with or without food (if liquid) . Swallow the capsules  whole and do not chew the m. 
2. Record the date, the number of capsules  taken, and when you took them.  
3. If you forg et to take your dose before 6:00PM, then do not take a dose that day.  Restart taking it the next day.  
4. If you have any questions or notice any side effects, please record them in the comments section.  Record the 
time if you should vomit.  
5. Please return the forms to your physician or your study coordinator when you go to your next appointment.  
Please bring your unused study medications and/or emp ty bottles with you to each clinic visit so that a pill count 
can be done.  
6. Avoid St. John’s Wort, Seville oranges, grapefruit, grapefruit juice, grapefruit hybrids, pummelos, and exotic 
citrus fruits from 7 days before you start taking PD 0332991 and throu ghout the entire study.   
Day Date  What time was 
dose taken?  # of capsules  
taken , if 
applicable  Comments  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 66 of 73 
 APPENDIX C: Pfizer Reportable Event Cover Sheet  
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 67 of 73 
 APPENDIX D: CYP3A4 Inhibitors, Inducers, and Substrates  
 
(Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University 
School of Medicine (2007). "http://medicine.iupui.edu/clinpharm/ddis/clinical -table/" Accessed 
01/22/14.)  
 
CYP3A4 Inhibitors - Avoid  
Indinavir  
Nelfinavir  
Ritonavir  
Clarithromycin  
Itraconazole  
Ketoconazole  
Nefazodone  
Erythromycin  
Grapefruit juice  
Verapamil  
Diltiazem  
Cimetidine  
Amiodarone  
Fluvoxamine  
Mibefradil  
Toleandomycin  
 
CYP3A4 Inducers – Avoid and Consider an Alternate Medication  
Carbamazepine  
Phenobarbital  
Phenytoin  
Pioglitazone  
Rifabutin  
Rifampin  
St. John’s wort  
Troglitazone  
 
CYP3A4 Substrates – Not Recommended , Consult PI before Use  
Clarithromycin  
Erythromycin  
Telithromycin  
Quinidine  3-OH 
Alprazolam  
Diazepam  3-OH 
Midazolam  
Triazolam  
Cyclosporine  
Tacrolimus  
Indinavir  
Ritonavir  
Protocol Version:  Amendment 6; 10/24/17   Page 68 of 73 
 Saquinavir  
Cisapride  
Astemizole  
Chlorpheniramine  
Amlodipine  
Diltiazem  
Felodipine  
Nifedipine  
Nisoldipine  
Nitrendipine  
Verapamil  
Atorvastatin  
Lovastatin  
Simvastatin  
Aripiprazole  
Boceprevir  
Buspirone  
Gleevec  
Haloperidol  
Methadone  
Pimozide  
Quinine  
Sildenafil  
Tamoxifen  
Telaprevir  
Trazodone  
Vincristine  
 
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 69 of 73 
 APPENDIX E: EORTC QLQ -C30 
 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by  circling the number that best applies to you. There are no "right" or "wrong" 
answers. The information that you  provide will remain strictly confidential.  
 
 Not 
at 
All A 
Little  Quite a 
bit Very 
Much  
1. Do you have any trouble doing strenuous activities,  
like carrying a heavy shopping bag or a suitcase?  1 2 3 4 
2. Do you have any trouble taking a long walk?  1 2 3 4 
3. Do you have any trouble taking a short  walk outside of 
the house?  1 2 3 4 
4. Do you need to stay in bed or a chair during the day?  1 2 3 4 
5. Do you need help with eating, dressing, washing  
yourself or using the toilet?  1 2 3 4 
During the past week:  Not 
at 
All A 
Little  Quite a 
Bit Very 
Much  
6. Were you limited in doing either your work or other 
daily activities?  1 2 3 4 
7. Were you limited in pursuing your hobbies or other  
leisure time activities?  1 2 3 4 
8. Were you short of breath?  1 2 3 4 
9. Have you had pain?  1 2 3 4 
10. Did you need to rest?  1 2 3 4 
11. Have you had trouble sleeping?  1 2 3 4 
12. Have you felt weak?  1 2 3 4 
13. Have you lacked appetite?  1 2 3 4 
14. Have you felt nauseated?  1 2 3 4 
15. Have you vomited?  1 2 3 4 
16. Have you been constipated?  1 2 3 4 
During the past week:  Not 
at 
All A 
Little  Quite a 
Bit Very 
Much  
17. Have you had diarrhea?      
18. Were you tired?      
19. Did pain interfere with your daily activities?      
20. Have you had difficulty in concentrating on things,  
like reading a newspaper or watching television?      
21. Did you feel tense?      
22. Did you worry?      
23. Did you feel irritable?      
24. Did you feel depressed?      
Protocol Version:  Amendment 6; 10/24/17   Page 70 of 73 
 25. Have you had difficulty remembering things?      
26. Has your physical condition or medical treatment  
interfered with your family  life?     
27. Has your physical condition or medical treatment  
interfered with your social  activities?      
28. Has your physical condition or medical treatment  
caused you financial difficulties?      
For the following questions please circle the number between 1 and 7 that  
best applies to you  
29. How would you rate your overall health  during the past week?  
1 2 3 4 5 6 7 
Very Poor       Excellent  
30. How would you rate your overall quality of life  during the past week?  
1 2 3 4 5 6 7 
Very Poor       Excellent  
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 71 of 73 
 APPENDIX F: FACT -H&N  
Below is a list of statements  that other  people  with your illness have said are important . Please 
circle  or mark one number per line to  indicate your response as  it applies to the past 7 days . 
Not 
PHYSICAL  WELL -BEING  at all A little  
bit Some - 
what  Quite  
a bit Very  
much  
 
 
 
GP1  
I have  a lack of energy  .................................................. .....  
0  
1  
2  
3  
4 
 
GP2 I have  nausea  .......................................................... ............  0 1 2 3 4 
 
GP3 Because  of my physical  condition,  I have  trouble  
meeting  the needs  of my family  .........................................   
0  
1  
2  
3  
4 
 
GP4 I have  pain ............................................................ ..............  0 1 2 3 4 
 
GP5 I am bothered  by side effects  of treatment  .........................  0 1 2 3 4 
 
GP6 I feel ill ................................................................ ...............  0 1 2 3 4 
 
GP7 I am forced  to spend  time in bed ........................................  0 1 2 3 4 
SOCIAL/FAMILY  WELL -BEING  Not 
at all A little  
bit Some - 
what  Quite  
a bit Very  
much  
 
 
 
GS1  
I feel close  to my friends  ................................................ ....  
0  
1  
2  
3  
4 
 
GS2 I get emotional  support  from  my family  ............................  0 1 2 3 4 
 
GS3 I get support  from  my friends............................................ . 0 1 2 3 4 
 
GS4 My family  has accepted  my illness  ....................................  0 1 2 3 4 
 
GS5 I am satisfied  with family  communication  about  my      
 illness................................................................ ..................  0 1 2 3 4 
 
GS6 I feel close  to my partner  (or the person  who is my main       
 support)  .............................................................. ................  0 1 2 3 4 
 
Q1 Regardless  of your current  level  of sexual  activity,  please  
answer  the following  question.  If you prefer  not to answer  it,      
 please  mark  this box and go to the next section.       
 
 
GS7 I am satisfied  with my sex life ........................................... . 0 1 2 3 4 
 
 
Protocol Version:  Amendment 6; 10/24/17   Page 72 of 73 
 Please circle or mark one number  per line to indicate your response  as it applies to the past 7 days  
EMOTIONAL  WELL -BEING  Not 
at all A little  
bit Some - 
what  Quite  
a bit Very  
much  
 
 
 
GE1  
I feel sad .............................................................. ...............   
0  
1  
2  
3  
4 
 
GE2 I am satisfied  with how I am coping  with my illness.........  0 1 2 3 4 
 
GE3 I am losing  hope  in the fight  against  my illnes s.................  0 1 2 3 4 
 
GE4 I feel nervous  .......................................................... ............  0 1 2 3 4 
 
GE5 I worry  about  dying  .................................................... ........  0 1 2 3 4 
 
GE6 I worry  that my condition  will get worse  ...........................  0 1 2 3 4 
 
FUNCTIONAL  WELL -BEING  Not 
at all A little  
bit Some - 
what  Quite  
a bit Very  
much  
 
 
 
 
GF1  
I am able to work  (include  work  at home)  .........................   
0  
1  
2  
3  
4 
 
GF2 My work  (include  work  at home)  is fulfilling....................  0 1 2 3 4 
 
GF3 I am able to enjoy  life................................................. ........  0 1 2 3 4 
 
GF4 I have  accepted  my illness.............................................. .... 0 1 2 3 4 
 
GF5 I am sleeping  well ..................................................... .........  0 1 2 3 4 
 
GF6 I am enjoying  the things  I usually  do for fun .....................  0 1 2 3 4 
 
GF7 I am content  with the quality  of my life right  now.............  0 1 2 3 4 
 
  
Protocol Version:  Amendment 6; 10/24/17   Page 73 of 73 
 Please circle or mark one number  per line to indicate your response  as it applies to the past 7 
days. 
ADDITIONAL  CONCERNS  Not at 
all A little  
bit Some - 
what  Quite  
a bit Very  
much  
 
 
 
H&N1   
I am able to eat the foods  that I like ...................................   
0  
1  
2  
3  
4 
 
H&N2  My mouth  is dry ..................................................... ............  0 1 2 3 4 
 
H&N3  I have  trouble  breathing  ................................................ ..... 0 1 2 3 4 
 
H&N4  My voice  has its usual  quality  and strength  .......................  0 1 2 3 4 
 
H&N5  I am able to eat as much  food as I want  .............................  0 1 2 3 4 
 
H&N6  I am unhappy  with how my face and neck  look.................  0 1 2 3 4 
 
H&N7  I can swallow  naturally  and easily  .....................................  0 1 2 3 4 
 
H&N8  I smoke  cigarettes  or other  tobacco  products  .....................  0 1 2 3 4 
 
H&N9  I drink  alcohol  (e.g. beer,  wine,  etc.)..................................  0 1 2 3 4 
 
H&N  
10 I am able to communicate  with others  ...............................  0 1 2 3 4 
 
H&N  
11 I can eat solid  foods................................................... .........  0 1 2 3 4 
 
H&N  
12 I have  pain in my mouth,  throat  or neck  ............................  0 1 2 3 4 
 